Protocol v4.2
16 JAN 20231Clinical Study Protocol
Protocol Title: C ontrolled Human Infection Mo del Challenge/Rechallenge: 
Shigella flexneri 2a and S. sonnei cross-protective antigens 
discovery in healthy adults in the [LOCATION_002]
Version 4.2 16 January 2023
PATH CVIA 088 
[ZIP_CODE] 
00017454 Protocol Version/Date :
Sponsor Number/Name: 
[CONTACT_497401]: JHU IRB Number:
CIR Number: CIR337 
Funder: The Bill and Melinda 
Gates Foundation
Sponsor: PATH 
Principal Investigator: [INVESTIGATOR_497282], MD
Center for Immunization Research
Department of International Health
Johns Hopkins Bloomberg School of Public Health
[ADDRESS_639587], HH, Ro om 205
Baltimore, MD [ZIP_CODE]
Associate Investigators: David Sack, MD
Jane Halpern, MD, MPH, Dr PH
Subhra Chakraborty PhD
Brittany Feijoo, MSN, FNP-BC
Kamal Dhanjani MPAS, PA-C, FCCM
Arthi Rameshkumar, MSPH
Barbara DeNearing, RN, BSN, CCRC
Bridgett Finley, BSN, RN
Center for Immunization ResearchJohns Hopkins Bloomberg School of Public Health
Daniel Selig, MD
Walter Reed Army Institute of Research (WRAIR)
Janine Danko, MD
Naval Medical Research Center
Epi[INVESTIGATOR_497283], PhD, MPH
Head, 
Translational and Clinical Research Department (TraCR)1&71XPEHU  1&7
Protocol v4.2 
16 JAN 2023 2 Naval Medical Research Center 
Research Monitor:   Anna P. Durbin, MD 
Professor, International Health 
Johns Hopkins Bloomberg School of Public Health 
 
 
Data Management:  The Emmes  Company, LLC  
    [ADDRESS_639588] 
    Rockville, MD [ZIP_CODE] 
     
 
Study Sites:   Center for Immuniza tion Research  
    Department of International Health 
    Johns Hopkins Bloomberg School of Public Health  
    [ADDRESS_639589] 
Suites 101,103, 112 
Baltimore, MD [ZIP_CODE] 
    
Laboratories:   Quest Diagnostics, Inc.,  
[ADDRESS_639590] / Meyer B-130 
Baltimore, MD [ZIP_CODE] –[ADDRESS_639591]. 
Baltimore, MD [ZIP_CODE] 
 
Immunology Laboratories
 Robert J. Cybulski Jr, PhD, D(ABMM) LTC(P), MS, US Army  
    Director, Bacterial Diseases Branch, WRAIR  
    Assistant Professor in Medicine, Uniformed Services University  
    Deputy Microbiology Consultant to the US Army Surgeon General  
     
 
Protocol v4.[ADDRESS_639592] Enteric Research Laboratory (JHSPH)  
[ADDRESS_639593] / W5616  
Baltimore, MD [ZIP_CODE]  
 
Research Laboratories  Johns Hopkins Biological Repository 
Johns Hopkins Bloomberg School of Public Health 
Room W6620 / [ADDRESS_639594].  
Baltimore, MD [ZIP_CODE] 
 
 
    Daniel Leung, MD MsC 
30 N 1900 E 
University of Utah, Infectious Diseases, 4B319  
Salt Lake City, UT Ԝ [ZIP_CODE]  
 
Antigen Discovery Inc (ADi) [ADDRESS_639595]
 
Suite E1100  
Baltimore, Maryland [ZIP_CODE]  
Phone: 410 -955-3193 
Toll-Free: [PHONE_020] 
Fax: 410 -502-0584 
Email: [EMAIL_9498] 
 
 
 
  
Protocol v4.2 
16 JAN 2023 4 Investigato r’s Agreement 
  Controlled Human Infection M odel Challenge/Rechallenge: Shigella flexneri  2a and S. sonnei 
cross-protective antigens disc overy in healthy adults in the Un ited States 
   “I have read this protocol and agree to conduct the study as out lined herein in accordance with 
International Conference on Harmonization Good Clinical Practic e Guideline and FDA and DoD 
Regulations. ” 
  
 
 Kawsar R. Talaat, MD          Date 
Principal Investigator  
  
[CONTACT_1738] v4.2 
16 JAN 2023 5 I. Table of Contents 
I. Table of Contents  .............................................................. ........................................... 5  
II. ABBREVIATIONS  .............................................................. .......................................... 10  
III. CLINICAL PROTOCOL SYNOPSIS  .............................................................. ............. 13  
IV. BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........................... 21  
1. Background Information-Clinical S ignificance and Pathogenicity of Shigella  .......... 21  
2. Rationale for Current Study  .............................................................. ................................ 21  
3. Previous Experience  .............................................................. ............................................ 21  
S. flexneri  2a Strain 2457T  .............................................................. ............................................................... .. 21 
S. sonnei  Strain 53G  .............................................................. ............................................................... ............ 22  
4. Dose and Administration Rationale  .............................................................. ................... 22  
V. STUDY HYPOTHESIS  .............................................................. ................................... 22  
VI. OBJECTIVES  .............................................................. ................................................. 22  
1. Primary Objective:  .............................................................. ............................................... 22  
2. Secondary Objective:  .............................................................. .......................................... 22  
3. Exploratory Objectives: ............................................................... ...................................... 22  
VII. ENDPOINTS  .............................................................. ................................................... 23  
1. Primary Endpoint  .............................................................. ................................................. 23  
2. Secondary Endpoints  .............................................................. .......................................... 23  
VIII.  STUDY DESIGN  .............................................................. ............................................. 24  
1. Overview  .............................................................. ...............................................................  2 4 
2. Description of Study Design  .............................................................. ............................... 25  
IX. STUDY POPULATION  .............................................................. ................................... 26  
1. Selection and Enrollment of Participants  .............................................................. ......... 26  
2. Inclusion Criteria:  .............................................................. ................................................. 26  
3. Exclusion Criteria:  .............................................................. ............................................... 26  
4. Continuing Eligibility Criteria to Proceed to Cohort 1B or 2B  ...................................... 27  
5. Access to Medical Records  .............................................................. ................................ 27  
X. STUDY PROCEDURES  .............................................................. ................................. 28  
1. Screening  .............................................................. .............................................................. 28 
2. Clinical Evaluations  .............................................................. ............................................. 28  
i. Monitoring During Inpatient Phase  .............................................................. .......................................... 28  
ii. Wearable Devices and PVT Monitoring  .............................................................. .................................. 29  
iii. Rehydration Procedures ............................................................... ........................................................... 29  
Protocol v4.2 
16 JAN 2023 6 iv. Treatment for Vomiting  .............................................................. .............................................................. 30 
v. Treatment for Fever or Pain  .............................................................. ...................................................... 30  
vi. Other Treatments  .............................................................. ............................................................... ........ 30  
3. Routine Discharge  .............................................................. ............................................... 30  
4. Early Discharge  .............................................................. .................................................... 31  
5. Monitoring During Outpatient Phase  .............................................................. ................. 31  
6. Concomitant Medications/Treatments  .............................................................. .............. 31  
XI. STUDY SCHEDULE  .............................................................. ...................................... 31  
1. Recruitment, Screening, and Enrollment of Study Volunteers:  ................................... 31  
2. JH200 Screening:  .............................................................. ................................................. 31  
3. Study-Specific Screening:  .............................................................. .................................. 32  
4. Enrollment  .............................................................. ............................................................. 3 3 
5. Study Days  .............................................................. ............................................................ 33  
i. Day -2 or -1, Admission to the  Inpatient Isolation Unit (Day 89  challenge 2)  .................................. 33  
ii. Day 1, Challenge Day (Day 90 challenge 2)  .............................................................. .......................... 34  
iii. Challenge  .............................................................. ............................................................... ..................... 34  
iv. Days 1 – 8, Planned Inpatient Days (Days 90-97 challenge 2)  ......................................................... 34  
v. Day 9, Planned Discharge Day (Day 98 challenge 2)  .............................................................. .......... 35  
vi. Day 15 Outpatient Follow-Up Visit (+/- 2 Days) (Day 104 challen ge 2)  ........................................... 35  
vii. Day 29 Outpatient Follow-Up Visit (+/- 4 Days) (Day 118 challen ge 2)  ........................................... 35  
viii. Day 57 Outpatient Follow-Up Visit (+/- 4 Days) (Day 146 challen ge 2)  ........................................... 35  
ix. Day 90 (-7/+28 days) Outpatient Visit OR readmission to the inp atient unit for second challenge: 
(Day 180 challenge 2)  .............................................................. ...............................................................  36 
x. Re-Admission for Second Challenge  .............................................................. ...................................... 36  
xi. Day 180/270 Follow-Up Visit  .............................................................. .................................................... 37  
6. Antibiotic Treatment  .............................................................. ............................................ 37  
7. Early Termination  .............................................................. ................................................. 37  
8. Laboratory procedures  .............................................................. ........................................ 38  
9. Microbiology:  .............................................................. ........................................................ 39  
10. Research Labs:  .............................................................. .................................................... 39  
11. Retention of Study Samples  .............................................................. ............................... 39  
XII. STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  ....................................... 40  
1. Shigella  Challenge Inoculum/Pr oduct Characterization  ............................................... [ADDRESS_639596] Administration  .............................................................. ....................................... 43  
6. Accountability Procedures for t he Investigational Products  ....................................... 43  
XIII.  ASSESSMENT OF SAFETY  .............................................................. ......................... 43  
1. Safety Monitoring-Vital Signs  .............................................................. ............................. 44  
2. Physical Examination  .............................................................. .......................................... 45  
3. Assessment of Stools  .............................................................. ......................................... 45  
4. Laboratory Assessments  .............................................................. .................................... 45  
5. IND Safety Reporting - Definitions  .............................................................. ..................... 47  
Adverse Event  .............................................................. ............................................................... ....................... 47  
Suspected Adverse Reaction  .............................................................. ............................................................. 4 7 
Solicited and Anticipated Adverse Events (Reactogenicity Events ) ........................................................... [ADDRESS_639597] (Assessment of Causalit y) ........................... 49  
7. Recording Adverse Events – Method/Timing  .............................................................. ... 50  
8. Duration of Follow-Up of Participants after Adverse Events  ....................................... 50  
9. Safety Assessments  .............................................................. ............................................ 51  
10. Reporting Adverse Events  .............................................................. .................................. 52  
11. Outcome Adjudication Committee  .............................................................. ..................... 52  
12. Reporting Serious and Unexpected Adverse Events  .................................................... 53  
13. Reporting to the Sponsor ............................................................... ................................... 53  
14. Reporting to the IRB  .............................................................. ............................................ 54  
15. Immediately Reportable Events - Pregnancy  .............................................................. ... 55  
16. AE-Related Withdrawal of Consent  .............................................................. ................... 55  
17. Pending Inspections/Issuance of Reports  .............................................................. ........ 56  
18. IND reporting  .............................................................. ........................................................ 56  
Annual  .............................................................. ............................................................... ..................................... 56  
Final  ………………………………………………………………………………………………………………………………………………………….……5 6 
19. Safety Criteria for Stoppi[INVESTIGATOR_497284]  ............................................................ 5 6 
20. Study Termination ............................................................... ............................................... 57  
XIV.  STUDY MONITORING  .............................................................. .................................. 57  
1. Monitoring  .............................................................. ............................................................. 5 7 
2. Data Entry  .............................................................. ............................................................. 5 7 
3. Data Management/Collection/Source Documents  ......................................................... 57  
Protocol v4.2 
16 JAN 2023 8 XV.  STATISTICAL CONSIDERATIONS  .............................................................. .............. 58  
1. Introduction  .............................................................. .......................................................... 58  
2. Volunteer Selection  .............................................................. ............................................. 58  
3. Definitions of populations to be analyzed  .............................................................. ........ 58  
4. Analysis  .............................................................. ............................................................... .. 59 
Baseline Data  .............................................................. ............................................................... ........................ 59  
Rates of Shigellosis  .............................................................. ............................................................... .............. 59  
Safety Analyses  .............................................................. ............................................................... .................... 59  
Immunology Analyses  .............................................................. ............................................................... .......... 59  
5. Sample Size Considerations  .............................................................. ............................... 60  
XVI.  OBLIGATIONS AND ROLES OF TH E SPONSOR, INVESTIGATOR, AND 
STUDY PERSONNEL  .............................................................. .................................... 61  
XVII.  QUALITY CONTROL AND ASSURANCE  .............................................................. . 61 
XVIII.  PROTOCOL DEVIATIONS  .............................................................. ......................... 61  
XIX.  PROTECTION OF HUMAN SUBJECTS  .............................................................. ...... 62  
1. Insurance and Indemnity ............................................................... .................................... 62  
2. Risks/Benefits  .............................................................. ...................................................... 62  
Risks Associated with Shigella  Infection  .............................................................. ............................................... 62  
Risks Associated with Tra nsmission of Challenge  .............................................................. ................................. 62  
Risks Associated with Antibiotics  .............................................................. .......................................................... 62  
Risks Associated w ith Saliva Collection  .............................................................. ................................................ 63  
Risks Associated with Nasal Swab : Risks occasionally associated  with nasal swabs may include discomfort with 
procedure, nasal irritation  .............................................................. ............................................................. 6 3 
Risks Associated with V enipuncture or IVs  .............................................................. ........................................... 63  
Risks Associated with  Wearable Data Collection: Risks may inclu de feeling uncomfortable about wearing a 
wrist device in public. The wrist  band may also cause some mino r wrist irritation.  .................................. [ADDRESS_639598]-Infec tious Irritable Bowel Syndrome (PI-IBS)  ......................................................... 63  
Risk of Breach o f Confidentiality  .............................................................. ........................................................... 64  
Risk of SARS-CoV-2 Exposure and Risk Mitigation  .............................................................. ............................. 64  
3. Risk Mitigation Strategies  .............................................................. ................................... 65  
4. Benefits  .............................................................. ............................................................... .. 66 
XX.  INFORMED CONSENT  .............................................................. .................................. 66  
1. Safeguards for Vulnerable Participants:  .............................................................. ........... [ADDRESS_639599] of Tables 
 
TABLE 1: DESCRIPTION OF STUDY GROUPS  .............................................................. ......................................... 24  
TABLE 2: REFERENCE RANGES AND ADVE RSE EVENT CODING FOR VITAL SI GNS PARAMETERS  ..... 44  
TABLE 3: REFERENCE RANGES AND ADVE RSE EVENT CODING FOR CLINICAL  HEMATOLOGY 
PARAMETERS  .............................................................. ............................................................... .............. 46  
TABLE 4: REFERENCE RANGES AND ADVE RSE EVENT CODING FOR BLOOD CH EMISTRY 
PARAMETERS  .............................................................. ............................................................... .............. 46  
TABLE 5: CHALLENGE INPATIENT PHASE SHIGELLA  INFECTION SOLICITED ADVERSE 
EVENT/ENDPOINT  .............................................................. ............................................................... ....... 52  
TABLE 6: CLASSIFICATION OF INTENSI TY OF DIARRHEA DURING THE OUT PATIENT PHASE  .............. 52  
TABLE 7: STUDY CONTACTS FOR REPORTING SERIOUS ADVERSE EVENTS  ............................................. 54  
TABLE 8: SAE INFORMATION TO B E REPORTED TO THE SPONSOR  ..............................................................  54 
TABLE 9: SCHEDULE OF PROCEDURE S FOR SUBJECTS RECEIVING ONE CHAL LENGE  ........................... 73  
TABLE 10: SCHEDULE OF PROCEDURES FOR SUBJECTS RECEIVING TWO CHA LLENGES  ...................... [ADDRESS_639600] of Figures 
 
FIGURE 1: STUDY SCHEMA  .............................................................. ............................................................... ... 25  
FIGURE 2: PRODUCTION CELL BANK FOR 2457T S. FLEXNERI  2A .............................................................. ............. 41  
FIGURE 3: SHIGELLA SONNEI STRAIN 53G  .............................................................. ............................................. [ADDRESS_639601] 
EDC Electronic data capture 
ELISA Enzyme-linked immunosorbent assay 
GCP Good Clinical Practice 
h Hours  
H2 blockers H2 receptor agonists 
HBsAg Hepatitis B surface antigen 
HCV Hepatitis C virus 
HIV-1 Human Immunodeficiency Virus 1 
HLA Human leukocyte antigen 
IATA International Air Transport Association 
ICF Informed Consent Form 
Protocol v4.2 
16 JAN 2023 11 ICH International Conference on Harmonisation 
IgG; IgA Immunoglobulin G; Immunoglobulin A 
IP Investigational Product 
IRB Institutional Review Board  
IV Intravenous 
JHSPH Johns Hopkins Bloomberg School of Public Health  
JHU Johns Hopkins University  
JHH Johns Hopkins Hospi[INVESTIGATOR_497285] (WRAIR) 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PE Physical Exam 
PI [INVESTIGATOR_497286]-IBS Post-infectious irritable bowel syndrome 
PSRT Protocol Safety Review Team 
PVT Psychomotor vigilance test 
QA Quality assurance 
QC Quality control 
RNA Ribonucleic acid 
SAE Serious adverse event 
SAP Statistical analysis plan 
SBA Serum bactericidal antibody 
SMP Safety Monitoring Plan 
SOP Standard Operating Procedure  
SSP Study Specific Procedure 
SWI Sterile water for injection 
TD Travelers’ diarrhea  
TMF Trial Master File 
TSA Trypticase soy agar 
Protocol v4.2 
16 JAN 2023 12 TSB Tryptic soy broth 
VS Vital signs 
WBC White blood cell 
WRAIR Walter Reed Army Institute of Research 
 
 
  
Protocol v4.2 
16 JAN 2023 13 III. CLINICAL PROTOCOL SYNOPSIS 
Protocol Title Controlled Human Infection Model Challenge/Rechallenge: Shigella  flexneri 2a 
and S. sonnei  cross- protective antigens discovery in healthy adults in the United 
States  
 
Name [CONTACT_497402] x Shigella flexneri  2a 2457T (lot 1617) 
x Shigella sonnei  53G (lot 1794) 
Study Site Johns Hopkins Center for Immunization Research 
Principal 
Investigator [INVESTIGATOR_497282], M.D. 
Study Hypothesis  Challenge with one species of Shigella  (Shigella flexneri  2a or Shigella sonnei ) will 
induce some cross -protective immunity such that a subset of volunteers will be pr otected 
upon challenge with the second strain. 
Study Rationale  The goal of this study is to better understand Shigella  immunity. The study will compare 
the shigellosis rate in subjects previously challenged with a h eterologous Shigella  
serotype to the attack rate in naïve subjects. Subsequent evalu ations of the immune 
response will seek to identify cross-protective Shigella  antigens which could improve 
upon the current requirement for serotype -specific O- antigens from the most common 
Shigella  species. 
 
Study Population Up to 54 healthy participants (ma le or non-pregnant, non-nursin g female), aged 18-50 
years (all inclusive)  from the Baltimore, MD-Washington, DC region and adjacent 
regions.  
 
Study Design 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 This is a single-center controlled human infection model (CHIM)  study designed to 
assess the cross -protective efficacy and markers of protection after challenge and 
heterologous rechallenge with Shigella  strains of different serotypes in naïve healthy 
adult volunteers.  
 
As shown in Table S1, a group of up to 13 naïve participants wi ll be challenged with 
1500 colony forming units (cfu) of S. sonnei  53G (Group 1A1). At least 3 months later, 
11 of these volunteers, who are willing and eligible for rechal lenge, along with up to 8 
newly recruited naïve participants, will be challenged with 150 0 cfu of S. flexneri  2a 
(Group 1B1). Additionally, n ine newly recruited naïve participants will be challenged 
with 1500 cfu of S. sonnei 53G (Group 1A2) and later 8 of these volunteers willing and 
eligible for rechallenge  will be rechallenged with 1500 cfu of S. flexneri 2a (Group 
1B2). An additional group of 13 naive participants will be challenged with 1500 cfu of 
S. flexneri  2a (Group 2A1). At least 3 months  later, up to 11 of those volu nteers from 
Group 2A1 willing and eligible to proceed to another challenge,  along with 5  or more 
naïve participants, will be challenged with 1500 cfu of S. sonnei 53G (Group 2B1) , and 
another group of up to 6 naive participants will be challenged with 1500 cfu of S. 
flexneri 2a  (Group 2A2). Each volunteer will be followed for [ADDRESS_639602] challenge.  
 
 
Table S1. Clinical trial study design. 
 
Protocol v4.2 
16 JAN 2023 14  
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
  
  
Group/cohort N Sub-
group N naïve  N veterans Challenge strain 
(1500 cfu/dose) 
1A 13 1 13 0 S. sonnei  53G 
 9 2 9 0 S. sonnei  53G  
1B 19 1 Up to 8 11 from 1A1 S. flexneri  2a 2457T 
 8 2 0 8 from 1A2 S. flexneri  2a 2457T  
2A 13 1 13 0 S. flexneri  2a 2457T 
 Up to 6 2 Up to 6 0 S. flexneri  2a 2457T  
2B Up to 16 1 5 Up to 11 from 
2A1 S. sonnei  53G 
 
Breakdown of study cohorts/groups : Each cohort is defined by [CONTACT_497336] (e.g., Cohort 1, S. sonnei , Cohort 2, S. flexneri  2a).  The groups refer 
to the admission; Group A is the first admission/challenge per cohort, B, the second 
admission/rechallenge. Within the A groups, all volunteers are naïve; within each of the 
B groups, up to [ADDRESS_639603] 
microbiological and molecular assays (detailed description give n in separate study 
specific procedure [ SSP]). If a participant is unable to provide a stool sample by 1300 
hours, s/he will be asked to obtain a rectal swab. Swabs will b e used starting the day 
after challenge.  
 
Mucosal and systemic antibody responses to the challenge strain s will be assessed 
throughout the study, as shown in the schedule of events.  
 
Antibiotic Treatment 
Routine antibiotic treatment with antibiotics to which the strains are susceptible will 
commence for all participants approximately [ADDRESS_639604]-challenge. All participants 
will be treated with trimethoprim 160 mg / sulfamethoxazole 800  mg orally twice daily 
for five days, or ciprofloxacin (500 mg orally twice daily for thre e days), or, 
alternatively, ampi[INVESTIGATOR_10312] (500 mg orally four times daily for three days). 
Early antibiotic treatment after challenge may commence when an y of the following 
criteria are identified and a study physician considers it to b e warranted:  
 
- When volunteers meet the primary endpoint (clinical definition of 
shigellosis) 
  OR 
- Oral temperature ≥ 39°C  
  OR 
Protocol v4.2 
16 JAN 2023 15 - Any other reason warranting the early treatment in the physicia n’s 
opi[INVESTIGATOR_497287], because of illness, a participant is unable to take oral antibiotics, intravenous 
antibiotics (e.g. , ciprofloxacin ) may be given at an appropriate dose based on weight and 
clinical status.  
 
Discharge Criteria  
All participants will be discharged from the inpatient unit when they are well, have taken 
at least [ADDRESS_639605]-
challenge. A follow -up visit approximately 6 months after challenge will be perform ed 
to inquire about the occurrence of any new chronic health condi tions (such as reactive 
arthritis, conjunctivitis, urethritis), serious health events, or hospi[INVESTIGATOR_602] , and to 
complete a functional bowel survey to assess for new-onset chro nic bowel problems. 
Study Procedures Screening and Consenting 
Initial screening will occur under a separately approved general screening protocol ov er 
the course of 1 – [ADDRESS_639606] low titers to the challenge strains, as determined by  O-antigen -
specific antibodies in the serum, will be eligible for enrollme nt. 
 
Eligible and willing participants will be invited to participate in an informed consent 
process where study information is presented in writing (ICF), view an audio/visual 
study brief, complete a comprehension assessment , and consent to study participation by 
[CONTACT_216381].  
 
Inpatient Admission and Challenge 
Each group will be admitted to the inpatient unit on Day -2 or -1. The day after 
admission, Day 1, each participant will be challenged with approximately 1500 cfu of 
the fully virulent Shigella  strain after a ≥90-minute fast and immediately following 
ingestion of a bicarbonate solution. Volunteers will fast for ≥90 additional minutes after 
challenge.  
 
Participants  will be selected for the rechallenge randomly, if they are elig ible and willing 
to continue with the study. The duration of the active study pe riod for participants who 
receive one dose of challenge is approximately 6 months ; for participants who receive 
both challenges , the active study period is about [ADDRESS_639607] (AESI) and Serious Adverse E vents 
(SAEs) will be collected for approximately [ADDRESS_639608] c hallenge.  
 
Outcome Adjudication Committee 
Protocol v4.2 
16 JAN 2023 16 To obtain an unbiased determination of the efficacy outcomes, a  blinded independent 
outcome adjudication committee will evaluate challenge outcome data after completion 
of the inpatient phase of the study for all cohorts.  
 
Primary 
Objective  To evaluate the cross-species protection conferred by a re-chal lenge with a Shigella  
species  of a different serotype. 
 
Primary 
Endpoint  The primary endpoint for outcomes following initial challenge a nd heterologous re-
challenge is shigellosis [1], defined as: 
 
- severe diarrhea 
OR 
- moderate diarrhea with fever OR with one or more moderate 
constitutional or enteric symptom OR ≥2 epi[INVESTIGATOR_9029] a 24-
hour period 
OR 
- dysentery: ≥2 loose stools with gross blood (hemoccult positive ) in 24 
hours AND fever OR ≥1 moderate constitutional/enteric symptom OR 
≥2 epi[INVESTIGATOR_9029] 24 hours  
Secondary 
Objective  To determine effects of previous  challenge when re-challenged w ith Shigella  of a 
different serotype on stool output and clinical symptoms.  
 
Secondary 
Endpoints  Secondary endpoints for this study following initial challenge and heterologous re-
challenge are: 
- Maximum 24-hour stool output 
- Percent of participants with severe diarrhea 
- Percent of participants with diarrhea of any severity 
- Total weight of grade 3-5 stools per participant 
- Percent of participants with nausea, vomiting, anorexia, abdomi nal pain/cramps 
rated as moderate to severe 
- Percent of participants who meet the definition of dysentery 
- Mean/median time to onset of diarrhea 
- Number of participants with more severe diarrhea (defined as ≥ 10 loose [grade 3 -5] 
stools within 24h or ≥1000 gr loose [grade 3 -5] stools within 24h) 
- Number of participants with fever 
- Shigella  clinical severity score post-challenge 
- Number of cfu of the challenge strain per gram of stool 
 
Note: Period of data collection for all secondary endpoints is during the inpatient period.  
Exploratory Objectives
 1. To determine IgG and IgA responses to Shigella  species specific lipopolysaccharide 
(LPS) upon challenge or rechallenge. 
2. To utilize novel analyses of immune responses, including antige n arrays, to identify 
potentially protective immune responses in individuals protected from shige llosis 
upon challenge or rechallenge. 
3. To identify potential protective antigens on the challenge orga nisms. 
4. To confirm that the serum IgG to the O-antigen is a correlate o f protection for 
shigellosis. 
5. To assist in the development of international standards against  Shigella  antigens.  
6. To measure mucosal and systemic immune responses to experimenta l infection. 
Protocol v4.2 
16 JAN 2023 17 7. To obtain and archive samples for future proteomics, inflammato ry marker, 
microbiome, and/or transcriptomics and systems biology efforts based on the 
recently published consensus schedule and events table [2]. 
8. To evaluate the cognitive and sleep impact of acute diarrhea us ing psychomotor 
vigilance testing (PVT) and actigraphy. 
9. To evaluate serum bactericidal antibody (SBA) titers against S. flexneri  2a 2457T 
and S. sonnei  53G (responders defined as ≥ 4-fold increase in SBA titer at designated 
timepoints post-initial challenge and heterologous re-challenge .  
10. To evaluate the ability of wearable-collected data to predict c linical and/or 
microbiological endpoints. 
Definitions Stool will be graded based on a standard stool grading scale as  follows [3]: 
 Grade 1 = Fully formed (normal)  
 Grade 2 = Soft (normal)  
 Grade 3 = Thick liquid (diarrheal)  
 Grade 4 = Opaque watery (diarrheal)  
 Grade 5 = Rice-water (diarrheal) 
 
x More severe diarrhea: ≥10 loose (grade 3 -5) stools within 24 hours (h) or ≥1000  
grams loose (grade 3-5) stools within any 24-hour window 
x Severe diarrhea: ≥6 loose (grade 3 -5) stools within 24h or >800 grams loose 
(grade 3-5) stools within any 24-hour window 
x Moderate diarrhea: 4 to 5 loose (grade 3-5) stools within 24h o r 401-800 gr ams 
loose (grade 3-5) stools within any 24-hour window 
x Mild diarrhea : ≥2 loose (grade 3 -5) stools weighing ≥200  grams within any 48-
hour window or 1 loose stool weighing ≥300  grams not meeting the definition 
for moderate or severe 
x Fever: measured oral temperature ≥ 38°C confirmed within about 20 min utes 
x Dysentery: ≥2 loose stools  (grade 3-5) with gross blood (hemoccult positive) in 
24 hours AND fever OR ≥1 moderate constitutional/enteric sympto m OR ≥2 
epi[INVESTIGATOR_9029] 24 hours 
x Constitutional/enteric symptom: nausea, abdominal cramps/pain, myalgia, 
arthralgia, malaise 
x Shigellosis disease severity will be assessed as previously des cribed [4]. 
Inclusion Criteria  1. Healthy adults, male or female, aged 18 to 50 years (all inclus ive) at the time of 
enrollment. 
2. General good health, without clinically significant medical his tory, physical 
examination findings, or clinical laboratory abnormalities per judgment of PI. 
3. Willingness to participate in the study after all aspects of th e protocol have been 
explained and written informed consent obtained. 
4. Completion of a training session and demonstrated comprehension  of the protocol 
procedures and knowledge of Shigella -associated illness by [CONTACT_15728] a written 
examination (70% passing score). 
5. Availability for the study duration, including all planned foll ow-up visits. 
6. Female participants must have a negative pregnancy test at screening and prior to 
each challenge. 
7. Female participants must agree to avoid pregnancy for [ADDRESS_639609] this documented (e.g., tubal ligation or hys terectomy).  
Protocol v4.[ADDRESS_639610] (within 30 da ys before 
enrollment). 
4. Positive enzyme- linked immunosorbent assay (ELIS A) and confirmatory tests for 
human immunodeficiency virus (HIV). 
5. Positive hepatitis C (HCV) ELISA and confirmatory test (e.g., HCV ribonucleic 
acid (RNA)). 
6. Positive hepatitis B virus surface antigen (HBsAg) by [CONTACT_6428]. 
7. Use of any medication that affects immune function (e.g., corti costeroids and 
others) within [ADDRESS_639611] challenge or planned  use during the active 
study period (topi[INVESTIGATOR_497288] ). 
8. Evidence of impaired immune function or immune compromise (know n 
immunodeficiency syndrome; either congenital, acquired, or iatr ogenic; active 
autoimmune disease; repeated serious infections without known c ause). 
9. IgA deficiency (serum IgA < 7 mg/dL or below the limit of detec tion of the assay). 
10. Positive blood test for HLA-B27. 
11. Personal or family history of an inflammatory arthritis. 
12. Currently pregnant or nursing. 
13. Have household contacts who are < 2 years old or > [ADDRESS_639612] patient care, in  a daycare center (for 
children or the elderly), or dir ect food handler; includes indi viduals who work directly 
with food in commercial establishments 
15. Evidence of current alcohol or drug dependence, or history of d ependence in the last 
6 months. 
16. Recent vaccination (including licensed vaccines) or receipt of an investigational 
product (within [ADDRESS_639613] 
challenge dose). Annual influenza vaccine, an emergency authori zed or licensed 
COVID-19 vaccine, or a TdaP or Td booster may be administered b eyond 14 days 
before and after each challenge. 
17. Treatment with immunoglobulins or blood products within 3 month s of challenge. 
18. Current or prior history of inflammatory bowel disease or irrit able bowel syndrome 
or abnormal stool pattern (>3/day or <3/week, or loose or liqui d stools). 
19. Chronic use of anti-diarrheal, anti- constipation, or antacid therapy; or use of these 
medications in the 7 days prior to challenge. 
20. Use of proton pump inhibitors or H2 blockers (H2- receptor antagonists) within 48 
hours prior to challenge. 
21. Use of antibiotics within 7 days prior to challenge. 
22. Known allergy to any 2 of the fo llowing antibiotics: ciprofloxa cin, trimethoprim -
sulfamethoxazole, or a penicillin  
23. Symptoms of travelers’ diarrhea ( TD) associated with travel to countries where 
Shigella  or other enteric infections are endemic (most of the developin g world) 
within [ADDRESS_639614] 5 years. 
25. Serum IgG titer > 2500 to either Shigella  flexneri  2a or Shigella sonnei  LPS. 
26. Any other criteria which, in the investigator’s opi[INVESTIGATOR_1649], would compromise the 
ability of the volunteer to participate in the study, the safet y of the study, or the 
results of the study. 
Safety 
Monitoring  The research monitor and PI [INVESTIGATOR_497289]. 
 
Research Monitor: The research mo nitor will function as an inde pendent safety advocate 
for participants. This individual will have the following responsib ilities: 
x Evaluate ongoing safety data and make recommendations in order to ensure 
participants ’ safety as required 
x Be available for consultation by [CONTACT_497337] m through the 
period of the clinical study in which there is an interaction w ith human 
participants 
x Be available to review all SAEs and other unanticipated problem s involving risk 
to participants 
x Provide clinical advice, in accordance with the study protocol,  on the clinical 
management of participants. This advice may include, but is not  limited to: 
• Decisions on “borderline” eligibility for enrollment  
• Confirmation and discussion of treatment decisions for difficul t clinical 
situations 
• Must document all clinical decis ions including date, time, and signature 
• Must communicate all decisions to the study PI [INVESTIGATOR_497290], which must be stored with participant source doc uments 
 
All SAEs must be reported , whether or not regarded as possibly attributable to the test 
articles or antibiotic. SAE reports will be provided to the Spo nsor, research monitor, and 
IRB(s). The investigator must report SAEs within one calendar d ay of becoming aware 
of the event by [CONTACT_756], fax , or e-mail (if appropriate) to the study contact [CONTACT_497338].  
 
Study Duration The expected duration of the trial is approximately [ADDRESS_639615] 
challenge. Participants will complete 1 – 2 screening visits, a consenting visit, 1 or 2 
inpatient stays of approximately 10 days each , and 5 (if only 1 challenge) or 8 (if 2 
challenges) post-challenge outpatient follow-up visits. 
 
Screening and consenting will occur in the 60 days prior to enr ollment. 
Sample Size 
 A total of up to 54 participants will be challenged in this stu dy (up to 110 will be 
consented to ensure a full c omplement of volunte ers). Based on Table S1, p articipants 
are delineated as follows:  
x S. flexneri  2a 2457T single challenge (n=16; 8 (2 in Group 2A1 and 6 in Group 
2A2) not selected for rechallenge, 8 rechallenge controls in Gr oup 1B1)  
Rechallenge controls are naïve subjects enrolled alongside vete ran subjects 
(receiving their second challenge) and both receive the same ch allenge agent to 
allow a fair comparison for the attack rate across the group.  
Protocol v4.2 
16 JAN 2023 20 x S. sonnei  53G single challenge (n=up to 8; 3 (2 in Group 1A1 and 1 in Gr oup 
1A2) not selected for rechallenge, 5 rechallenge controls in Gr oup 2B1) 
x S. flexneri  2a 2457T challenge followed by S. sonnei  53G challenge (n=11 
veterans in Group 2B1) 
x S. sonnei  53G challenge followed by S. flexneri  2a 2457T challenge (n=19 
veterans in Groups 1B1 and 1B2) 
 
Presuming a shigellosis rate of 70% in naïve participants, a sa mple size of 16 
participants will yield 95% confid ence intervals (asymptotic es timates) of 48-92% , while 
a sample size of 8 participants will yield 95% confidence interval (asymptotic est imates) 
of 38-100%. Presuming an ability to pool naïve participants, a sa mple size of 19 
participants in the previously S. sonnei 53G challenged arm and 16 participants in the S. 
flexneri 2457T naïve arm provides a > 80% power to detect a shigellosis risk difference 
of 46% presuming a ≥70% attack rate in Shigella  naïve participants, while a sample size 
of 11 participants in the previously S. flexneri  2457T challenged arm and 8 participants 
in the S. sonnei 53G naïve arm provides a >80% power to detect a shigellosis ris k 
difference of 60% presuming a ≥70% attack rate in Shigella  naïve participants (based on 
a Pearson’s chi -squared test for proportional differences and a 2-sided alpha =0.05). 
Statistical 
methods and 
analysis  All AEs will be summarized and compared between groups. Safety data, including AEs, 
stool information, specified vital signs, and laboratory tests,  will be listed by [CONTACT_236886].  
 
Descriptive statistics (n, mean, standard deviation, median and  ranges for continuous 
variables, percentages for categorical variables) will be compi [INVESTIGATOR_497291]. The 
attack rate of shigellosis will be estimated along with 95% con fidence intervals (both 
asymptotic estimates and exact) for each study group. Attack ra tes between Shigella  
naïve participants and previously challenged participants will be compared using a 
Pearson’s chi -squared or Fisher’s exact test, as appropriate.  
 
Serologic and cellular assessments of the immune response will be conducted to assess 
for potentially protective responses in the volunteers resistan t to the development of 
shigellosis. Comparisons across groups of single immune paramet ers reported as 
continuous variables (e.g., reciprocal log 10 titers) will be made utilizing t- tests and one-
way analysis of variance , Wilcoxon rank-sum, or Kruskal-Wallis H tests, as appropriate. 
Comparisons of responses within groups over time will be made u tilizing appropriate 
paired analyses. Immune parameters that are nominal in nature ( e.g., responder status) 
will be compared using chi -squared or exact tests, as appropriate. Additionally, 
comparisons of immune response profiles, assessing multiple imm une parameters 
simultaneously , will be explored utilizing multivariable regression models, pri ncipal 
component analyses, and/or other multivariable methods , as appropriate. 
 
All hypothesis testing will be conducted using a 2-sided alpha =0.05. 
 
 
Protocol v4.2 
16 JAN 2023 21 IV. BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE 
ͳǤ Ǧ Shigella
Shigella , a major cause of bacillary dysentery, is an enteric bacterium  that can cause 
inflammatory diarrhea. Shigella has long been recognized as a cause of moderate and severe 
diarrhea and dysentery, with a high incidence among children re siding in low- and middle-income 
countries [5, 6]. Recent studies highlight the continued burden  of disease and provide data for 
burden estimates [7-11]. In a ddition to an estimated 212,438 an nual deaths in people of all ages 
[12], children under 5 years of age experience nearly 75 millio n cases of shigellosis each year, 
leading to stunting and wasting [12-14]. Shigella  also poses a significant enteric disease threat to 
deploying military forces and international travelers [15]. 
 
ʹǤ 
This is a human challenge study d esigned to assess the cross-pr otective efficacy and markers of 
protection after challenge and heterologous rechallenge with di fferent Shigella  strains in naïve 
volunteers. The study would look for novel, cross-protective Shigella  antigens which could 
improve upon the current requirement for serotype-specific O-an tigens from the most common 
species, S. flexneri  2a, 3a, and 6, and S. sonnei . Such antigens could be used as carrier proteins in 
third-generation glycoconjugate vaccines or act as stand-alone subunit vaccines to help broaden 
vaccine coverage. 
 
͵Ǥ 
The Shigella  Controlled Human Infection Model (CHIM) has been in use to eva luate the efficacy 
of investigational Shigella vaccines since the studies of Shaughnessy and colleagues in 194 6 
among prison inmates in Joliet, Illinois [16]. Since then, CHIM  trials evaluating Shigella vaccine 
candidates have been conducted at several sites in the United S tates, mostly with S. flexneri 2a 
(strain 2457T) [17-19] and S. sonnei (strain 53G) [20, 21], but also with wild-type and toxin-
minus mutants of S. dysenteriae  type 1 [19, 20, 22-27]. Additi onally, trials with 53G  have been 
conducted in Thailand [28, 29]. Previous field and CHIMs studie s have indicated that infection 
with specific Shigella  serotypes will induce protection against of a similar “O” serot ype but the 
antigens associated with cross-s erotype protection are not as w ell understood (Levine MM et al. 
2007).  
 
 S. flexneri ʹʹͶͷ͹
S. flexneri 2a has had the greatest range of doses tested for strain 2457T;  ranging from 100 to 1 x 
108 colony forming units (cfu) [19].  
 
Experimental S. flexneri  2a challenge was first attempted in the late 1960s in an effor t to develop 
a safe and reproducible model for rapid and accurate evaluation  of the efficacy of candidate 
Shigella  vaccines in humans [13]. The 2457T S. flexneri  2a strain that will be utilized in this 
study as a challenge strain is a well-characterized Shigella  strain manufactured under current 
Good Manufacturing Practice (cGMP) conditions at the WRAIR Pi[INVESTIGATOR_48085] t BioProduction Facility in 
Silver Spring, Maryland. This strain was originally isolated fr om a clinically ill patient in Japan in 
the early 1950s and has most frequently been given to volunteer s participating in IND studies 
evaluating treatment or preventive intervention for the control  and clinical management of 
shigellosis [19]. The 2457T strain is also covered by [CONTACT_497339] m anufacturing master file registered 
with the FDA (BB-MF-3408). In all, more than [ADDRESS_639616] 
likely to cause dysentery. The 2457T strain has been used in 15  published trials at doses ranging 
from 100 to 108 cfu [19], and additional challenge studies carried out by [CONTACT_497340] v4.2 
16 JAN 2023 22 Immunization Research (CIR) in recent years that have yet to be  published. Diarrhea attack rates 
are somewhat dose-related under 1400 cfu, but plateau at higher  doses to approximately 60 to 
80% [19]. The dose of [ADDRESS_639617] [23, 30, 31].  In total, the CIR has conducted [ADDRESS_639618] dose in 
challenge studies. This strain is susceptible to the antibiotic s that will be used for treatment 
(ciprofloxacin, trimethoprim-sulfamethoxazole, ampi[INVESTIGATOR_10312]). 
 
 S. sonnei ͷ͵

The second most commonly studied strain ( S. sonnei  53G) has historically been used in low 
inoculum doses, ranging between 400 and 500 organisms, with rel atively low diarrhea and 
dysentery attack rates. This stra in has been utilized at a numb er of sites in the US (in 296 adults) 
and in Thailand (in 56 adults), including at the CIR by [CONTACT_497341] (Unpublished). 
Recently, a lyophilized preparation of this strain has been man ufactured under cGMP conditions 
at the WRAIR Pi[INVESTIGATOR_497292] (PBF) to simplify the  inoculum preparation process. 
A dose-ranging study was conducted at Cincin nati Children’s Hospi[INVESTIGATOR_497293]. The challenge model 
demonstrated an acceptable safety profile, with no signs of ear ly onset or particularly aggressive 
disease. Among subjects receiving the highest dose (1760 cfu), 70% developed moderate to 
severe diarrhea, 50% had dysentery, and 40% had fever. A dose i n the range of 1500 to 2000 cfu 
was identified as the optimal dose for a reproducible diarrhea attack rate of ≥60% [32].  This 
strain is susceptible to the antibiotics that will be used for treatment (ciprofloxacin, trimethoprim-
sulfamethoxazole, ampi[INVESTIGATOR_10312]). 
 
ͶǤ 
Multiple studies have been carried out over the last [ADDRESS_639619] of these studies [1, 3]. This study is in compliance 
with those guidelines.  
V. STUDY HYPOTHESIS 
Challenge with one species of Shigella  (Shigella flexneri  2a or Shigella sonnei ) will induce some 
cross-protective immunity such that a subset of volunteers will  be protected upon challenge with the 
second strain.  
VI. OBJECTIVES 
ͳǤ ǣ
To evaluate the cross-species protection conferred by a re- challenge with a Shigella  species of 
a different serotype.  
 
ʹǤ ǣ
To determine effects of previous  challenge when re-challenged w ith Shigella  of a different 
serotype on stool output and clinical symptoms. 
 
͵Ǥ ǣ
1. To determine IgG and IgA responses to Shigella  species-specific lipopolysaccharide (LPS) 
upon challenge or rechallenge.  
 
 
Protocol v4.[ADDRESS_639620]  Shigella  antigens. 
6. To measure mucosal and systemic immune responses to experimenta l infection. 
7. To obtain and archive samples for future proteomics, inflammato ry marker, microbiome, 
and/or transcriptomics and systems biology efforts based on the  recently published consensus 
schedule and events table [2]. 
8. To evaluate the cognitive and sleep impact of acute diarrhea us ing psychomotor vigilance 
testing (PVT) and actigraphy.  
9. To evaluate serum bactericidal antibody (SBA) titers against S. flexneri  2a 2457T and S. 
sonnei  53G (responders defined as ≥ 4-fold increase in SBA titer at designated timepoints 
post-initial challenge and heterologous re-challenge.  
10. To evaluate the ability of wearable-collected data to predict c linical and/or microbiological 
endpoints.  
VII. ENDPOINTS 
ͳǤ 
The primary endpoint for outcomes following initial challenge a nd heterologous re-challenge is 
the onset of shigellosis, defined as: 
 
x Severe diarrhea: ≥6 loose (grade 3 -5) stools within 24h or >800gr loose (grade 3-5) stools 
within 24h 
OR 
x Moderate diarrhea (4 to 5 loose stools within 24 hr or 401-800g r loose (grade 3-5) stools 
within 24h) with fever OR with one or more moderate constitutio nal or enteric symptom OR 
≥2 epi[INVESTIGATOR_9029] a 24 -hour period 
 
OR 
 
x Dysentery: ≥2 loose stools wit h gross blood (hemoccult positive ) in 24 hours AND  fever OR 
≥1 moderate constitutional/enteric symptom OR ≥2 epi[INVESTIGATOR_9029] 24 hours  
 
Fever:  oral temperature ≥ 38°C confirmed within about 20 min  
 
Constitutional/Enteric Symptom:  nausea, abdominal cramps/pain, myalgia, arthralgia, malaise 
 
ʹǤ 
Secondary endpoints for this study following initial challenge and heterologous re-challenge are: 
- Maximum 24-hour stool output  
- Percent of participants with severe diarrhea 
- Percent of participants with diarrhea of any severity 
- Total weight of grade 3 – 5 stools per participant 
- Percent of participants with nausea, vomiting, anorexia, abdomi nal pain/cramps rated as 
moderate to severe 
- Percent of participants who meet the definition of dysentery 
 
 
Protocol v4.2 
16 JAN 2023 24 - Mean/median time to onset of diarrhea 
- Number of participants with more severe diarrhea (defined as ≥1 0 loose [grade 3 -5] 
stools within 24h or ≥1000 gr loose [grade 3 -5] stools within 24h) 
- Number of participants with fever 
- Shigella  clinical severity score post-challenge 
- Number of cfu of the challenge strain per gram of stool 
 
Note: Period of data collection for all secondary endpoints is during the inpatient period.  
VIII.  STUDY DESIGN 
ͳǤ 
This study will be conducted in the isolation unit at the CIR I npatient Unit, located at the Johns 
Hopkins Bayview Medical Center. This study will be a single-cen ter human challenge study designed 
to assess the cross-protective efficacy and markers of protecti on after challenge and heterologous 
rechallenge with different Shigella  strains in naïve healthy adult volunteers (see Figure 1: Study 
Schema ). 
 
Description of study groups as shown in table 1 below:   
Cohort 1, group 1A1: [ADDRESS_639621] 
3 months later, group 1B1: 11 of t he participants from group 1A 1 (who are willing and eligible to 
proceed to another challenge) , along with up to 8 naïve partici pants (group 1B1), will be 
challenged with 1500 cfu of S. flexneri  2a. Up to  9 newly recruited naïve participants will be 
challenged with 1500 cfu of S. sonnei 53G (Group 1A2)  and later 8 of these volunteers willing 
and eligible for rechallenge will be rechallenged with 1500 cfu  of S. flexneri  2a (group 1B2).  
Cohort 2, group 2A1: [ADDRESS_639622] 3 months later, group 2B1: up to 11 of those volunteers f rom Group 2A1 (who are willing 
and eligible to proceed to another challenge), along with 5 or more naïve participants (group 
2B1), will be challenged with 1500 cfu of  S. sonnei  53G, and another group of up to 6 naive 
participants will be challenged with 1500 cfu of S. flexneri  2a (group 2A2). Each volunteer will 
be followed for [ADDRESS_639623] challenge.   
 
 Table 1: Description of Study Groups 
Group/
cohort N Sub-
group N naïve  N veterans Challenge strain 
(1500 cfu/dose) 
1A 13 1 13 0 S. sonnei  53G 
 9 2 9 0 S. sonnei  53G  
1B 19 1 Up to 8 11 from 1A1 S. flexneri  2a 2457T 
 8 2 0 8 from 1A2 S. flexneri  2a 2457T  
2A 13 1 13 0 S. flexneri  2a 2457T 
 Up to 6 2 Up to 6 0 S. flexneri 2a 2457T 
2B Up to 16 1 5 Up to 11 from 2A1 S. sonnei  53G 
. 
Breakdown of study cohorts/groups: Each cohort is defined by [CONTACT_497342] 
(e.g., Cohort 1, S. sonnei , Cohort 2, S. flexneri  2a).  The groups refer to t he admission; Group A is the 
first admission/challenge per cohort, B, the second admission/r echallenge. Within the A groups, all 
volunteers are naïve; within each of the B groups, up to 20 vol unteers will be veterans from the A group 
and up to 10 volunteers will be naïve. The numbers after the le tter e.g. 1A1, denote subgroups that 
occurred at different admissions. 
 
 
 
Protocol v4.2 
16 JAN 2023 25 Figure 1: Study Schema 
 
 
The CIR Inpatient Unit is a 30-bed dorm-like facility for clini cal trials. Each group will be 
admitted together to the inpatient unit for up to [ADDRESS_639624] for 90 addi tional minutes after challenge.  
 
The duration of the active study period for participants who re ceive one dose of challenge is 
approximately 6 months; for participants who receive both chall enges, the active study period is 
about 9 months from enrollment, not including up to 60 days dur ing the screening period. 
 
ʹǤ 
This is a Shigella  controlled human infection study with a goal to assess the cro ss-protective 
efficacy and markers of protection after challenge and heterolo gous rechallenge with different 
Shigella  strains in naïve healthy, 18 to 50 year-old, non-pregnant volu nteers. 
 
The study will be divided into 3 p arts; about 2/3 of the partic ipants will repeat parts 2 and 3: 
1. Screening (usually 2 visits; some visits will be performed unde r a separate, IRB-approved 
 screening protocol) (see Section XI for details)  
2. Admission and challenge phase  
3. Follow-up phase (outpatient visits at Study Days 15, 29, 57, 90 , and 180)  
 
All potential volunteers will be screened for titers to S. flexneri  and S. sonnei  IgG. Those who 
meet eligibility criteria will be admitted to the inpatient uni t and receive the challenge strain 
(Investigational Product). Blinding will not be employed in thi s study as all subjects in each 
cohort will be receiving the same challenge strain.  However, t he adjudication of clinical 
outcomes will be blinded to both strain and cohort. Participant s are considered enrolled once they 
receive the investigational challenge. Volunteers will be monit ored by [CONTACT_45914] 24/[ADDRESS_639625]-
challenge until participants are eligible for discharge. Stool samples for culture and research 54 enrolled
Group 1A:
22 challenged with S. sonnei
Subgroup 1:
13 challenged with 
S. sonneiSubgroup 2: 
9 challenged with 
S. sonnei
Group 1B: 
27 challenged with 
S. flexneri 2a
Subgroup 1:
11 veterans from Group 1A1 and 8 
veterans from group 1A2Subgroup 2:
8 naive challenged with
S. flexneri 2aGroup 2A: 19 challenged with S. 
flexneri 2a 
Group 2B:
11 veterans from Group 2A  
challenged with S. sonneiUp to 5 naive challenged with S. 
sonnei
Up to 6 naive challenged with S 
flexneri
 
 
Protocol v4.2 
16 JAN 2023 26 testing will be collected daily; blood, nasal swabs, and saliva  will be collected at specified time 
points as per the schedule of events. Volunteers will be eligib le for discharge once they have 
received at least [ADDRESS_639626] 2 consecutive negative stools for Shigella . 
 
Trial Schedule : 
See Table 9: Schedule of Procedures for Subjects Receiving One Chal lenge  and Table 10: 
Schedule of Procedures for Subjects Receiving Two Challenges . 
IX. STUDY POPULATION 
ͳǤ 
Participants will be recruited from the Baltimore, MD-Washingto n, DC region and surrounding 
areas via advertisements and word of mouth and screened at the CIR. A sufficient number will be 
screened to provide for the number planned to challenge, with s ufficient alternates to allow for 
last-minute dropouts. The total t arget is 65 participants enrol led. Once challenged, subjects will 
not be replaced. 
 
ʹǤ ǣ
Participants must meet all criteria listed below to be included in the study: 
1. Healthy adults, male or female, aged 18 to 50 years (all inclus ive) at the time of 
enrollment. 
2. General good health, without clinically significant medical his tory, physical examination 
findings, or clinical laboratory abnormalities per judgment of PI. 
3. Willingness to participate in the study after all aspects of th e protocol have been explained 
and written informed consent obtained. 
4. Completion of a training session and demonstrated comprehension  of the protocol 
procedures and knowledge of Shigella -associated illness by [CONTACT_15728] a written examination 
(70% passing score). 
5. Availability for the study duration, including all planned foll ow-up visits. 
6. Female participants must have a n egative pregnancy test at scre ening and prior to each 
challenge.  
7. Female participants must agree to avoid pregnancy for [ADDRESS_639627] 
this documented (e.g., tubal ligation or hysterectomy).  
8. Willingness to refrain from part icipation in a study of another  investigational agent for [ADDRESS_639628] challenge dose.  
 
͵Ǥ ǣ
Participants meeting any of the exclusion criteria listed below must be excluded from 
participating in the trial: 
1. Presence of a significant medical or psychiatric condition that  in the opi[INVESTIGATOR_497294]. Some medical  conditions that are 
adequately treated and stable would not preclude entry into the  study. 
2. Clinically significant abnormalities in screening on physical e xam or screening laboratory 
results as determined by [CONTACT_976] [INVESTIGATOR_497295]. 
3. Recent receipt of another investigational product (within 30 da ys before enrollment). 
4. Positive enzyme-linked immunoso rbent assay (ELISA) and confirma tory tests for human 
immunodeficiency virus (HIV). 
5. Positive hepatitis C Virus (HCV) ELISA and confirmatory test (e .g., HCV RNA). 
6. Positive hepatitis B virus surface antigen (HBsAg) by [CONTACT_6428]. 
 
 
Protocol v4.2 
16 JAN 2023 27 7. Use of any medication that affects immune function (e.g., corti costeroids and others) 
within [ADDRESS_639629] challenge or planned use dur ing the active study period 
(topi[INVESTIGATOR_497296]).  
8. Evidence of impaired immune function or immune compromise (know n 
immunodeficiency syndrome; either congenital, acquired, or iatr ogenic; active 
autoimmune disease; repeated serious infections without known c ause). 
9. IgA deficiency (serum IgA < 7 mg/dL or below the limit of detec tion of the assay). 
10. Positive blood test for HLA-B27. 
11. Personal or family history of an inflammatory arthritis. 
12. Currently pregnant or nursing. 
13. Have household contacts who are < 2 years old or > [ADDRESS_639630] patient care, in  a daycare center (for 
children or the elderly), or dir ect food handler; includes indi viduals who work directly 
with food in commercial establishments 
15. Evidence of current alcohol or drug dependence, or history of d ependence in the last 6 
months. 
16. Recent vaccination (including lic ensed vaccines) or receipt of an investigational product 
(within [ADDRESS_639631] challenge dose). 
Annual influenza vaccine, an emergency authorized or licensed C OVID-19 vaccine, or a 
TdaP or Td booster may be administered beyond 14 days before an d after each challenge. 
17. Treatment with immunoglobulins or blood products within 3 month s of challenge. 
18. Current or prior history of inflammatory bowel disease or irrit able bowel syndrome or 
abnormal stool pattern (>3/day or <3/week, or loose or liquid s tools). 
19. Chronic use of anti-diarrheal, anti-constipation, or antacid th erapy; or use of these 
medications in the 7 days prior to challenge. 
20. Use of proton pump inhibitors or H2 blockers (H2-receptor antag onists) within 48 hours 
prior to challenge. 
21. Use of antibiotics within 7 days prior to challenge. 
22. Known allergy to any 2 of the fo llowing antibiotics: ciprofloxa cin, trimethoprim-
sulfamethoxazole, or a penicillin. 
23. Symptoms of travelers’ diarrhea ( TD) associated with travel to countries where Shigella  or 
other enteric infections are endemic (most of the developi[INVESTIGATOR_497297]) within [ADDRESS_639632] 5 years. 
25. Serum IgG titer > 2500 to either Shigella  flexneri  2a or Shigella sonnei  LPS. 
26. Any other criteria which, in the investigator’s opi[INVESTIGATOR_1649], would compromise the ability of 
the volunteer to participate in the study, the safety of the st udy, or the results of the study. 
 
ͶǤ ͳʹ
1. Must continue to meet incl usion criteria above. 
2. Must not meet any of exclusion criteria 1-21 and 24 (IgA, HLA-B 27, HIV, HCV, and 
HBsAg will not be repeated). 
3. All study subjects with Serious Adverse Events (SAEs) related t o the primary challenge 
will be excluded from a repeat (second) challenge. 
 
ͷǤ 
A medical history will be obtained directly from each participa nt. Medical records will not be 
requested unless there is a need to clarify a question in the p articipant ’s medical history or if the 
participant had an intercurrent illness or injury requiring med ical care during the study. Medical 
records will not be requested without a signed medical release and the informed consent of the 
 
 
Protocol v4.2 
16 JAN 2023 28 participant. Informed consent for the medical release will be o btained from each participant at the 
beginning of the study. 
X. STUDY PROCEDURES 
ͳǤ 
The CIR will use a screening protocol approved by [CONTACT_497343] 
(JHSPH) Institutional Review Board (IRB) in recruiting particip ants for this study. The screening 
protocol is entitled “Screening o f adult volunteers for eligibi lity to participate in clinical studies 
evaluating investigational vaccines, antimicrobial agents, or d isease prevention measures or the 
pathogenesis of infectious agents” CIR 200, JHSPH IRB 00010083. Participants will be made 
aware that the screening process may take several visits to com plete. Once consented, using this 
screening protocol, a medical history/exam and a series of clin ical laboratory tests will be 
completed to rule out occult illness and pregnancy (as per Sect ion XI, 8). Participants who have ≤ 
2 mild (grade 1) non-hematologic abnormalities may be included if the PI [INVESTIGATOR_497298]. P articipants with > 2 mild 
abnormalities may be included in the study at the discretion of  the PI [INVESTIGATOR_497299]. Participants with clinical laboratory abnorma lities >grade [ADDRESS_639633], and sign the s tudy Informed Consent Form (ICF) 
may be eligible for the study.  Informed consent is an ongoing process which includes the ICF. 
Participants will watch an audio/visual presentation of the stu dy after which they will be given an 
opportunity to ask any questions. Each prospective participant will be given the written, IRB-
approved informed consent, allowed ample time to read the conse nt, allowed to ask questions 
about the study, have his/her questions answered, and given tim e to decide if he/she would like to 
participate in the study. To doc ument participants’ understandi ng of informed consent, 
immediately before the consent is signed, the person obtaining consent will administer a 
comprehension test. Incorrect answers will be discussed with pa rticipants to reinforce the consent. 
A final acceptable test score is 70% or more answered correctly . Participants who fail the 
comprehension test on the first attempt may retake the comprehe nsion test on the same day, or 
they may come back on a separate visit to retake the test. Part icipants failing after two attempts 
are not eligible for study enrollment. No coercion or influence  is allowed in obtaining 
participants’ consent. Before participants participate in the s tudy, consent forms will be signed 
and dated by [CONTACT_497344] [INVESTIGATOR_1461]. Par ticipants will receive copi[INVESTIGATOR_497300]. As part of the consent p rocess, participants will also be 
asked to read and sign additional IRB-approved forms including but not limited to, a Medical 
Records/Lab Results Release, alternate information form, and in patient guidelines, with an 
opportunity to ask questions, if relevant.  
 
As part of the pre-inpatient period, eligible subjects may be a sked to perform a 5-minute baseline 
psychomotor vigilance test (PVT). Additionally, subjects will b e provided a smartphone and 
actigraphy devices to be worn starting up to [ADDRESS_639634]-
discharge follow-up visit (study day 15 ± 2 days). 
 
ʹǤ 
Ǥ 
Eligible participants will be admitted to the CIR inpatient fac ility on the Johns Hopkins 
Bayview campus on Day -2 or -1. Once challenged (Day 1), they w ill be monitored daily 
while in the inpatient unit for the development of shigellosis,  including general, 
 
 
Protocol v4.[ADDRESS_639635] udy physician/nurse 
practitioner/physician assistant and solicitation of adverse ev ents (as per list in Section XIII, 
5). Additionally, participants will be examined for symptoms and  signs of dehydration, 
including thirst, dizziness on standing, decreased skin turgor,  and dryness of mucous 
membranes. Vital signs will be recorded three times daily (four  times on challenge day), and 
more often when participants are ill.  If participants develop moderate or severe diarrhea, 
postural blood pressure and pulse will be measured as necessary  for clinical management 
according to the judgment of the clinician. 
 
A clinician will conduct a daily medical interview and focused physical exam to assess health 
status and treat as indicated. All stools will be collected for  weighing and grading [3]. 
Following Shigella  challenge, up to 3 stool samples will be collected daily for c ulture as per 
study specific procedure (SSP) starting the day after challenge . If a participant is unable to 
provide a stool sample by 1300 hours, s/he will be asked to obt ain up to 3 rectal swabs. 
Swabs will be used starting the day after challenge. 
 
Ǥ 
An exploratory assessment of the bidirectional relationships be tween sleep, cognitive 
performance, and shigellosis will be conducted with the use of continuous wrist actigraphy 
and PVT monitoring. Heart rate and skin temperature may also be  collected by [CONTACT_497345]. These outcomes will not be utilized as part of the reg ulatory safety, immunogenicity, 
or efficacy evaluations of the study products; they are explora tory in nature and will not be 
retained in the regulatory file. Missed PVTs will not be consid ered protocol deviations. 
Management of symptoms associated with Shigella  challenge or other illness will have 
priority over completion of PVTs. 
 During screening, participants will be issued two wrist-worn de vices and a smartphone for 
collection of actigraphy, heart rate, and skin temperature data . (Each device will collect 
different information. There will be no GPS information gathere d by [CONTACT_42093]).  Subjects 
will wear these devices starting up to [ADDRESS_639636]-
discharge follow-up visit (study day 15 ± 2 days). Subjects wil l be asked to complete a brief 
survey about how they are feeling each day using the smartphone . These surveys will not be 
used to determine medical history or clinical endpoints; they a re exploratory in nature and 
will not be retained in the regulatory file. Five-minute PVT te sts will be performed by [CONTACT_497346] a day. Analyses will explore symptom presence/severity, while 
adjusting for sleep cycles and other confounding variables, as appropriate. Additional 
exploratory assessments will include evaluations of immune acti vation and cognitive 
performance by [CONTACT_497347]. These data wi ll be collected for 
additional exploratory assessments beyond the scope of this pro tocol. 
 
Ǥ 
Participants passing grade 3-[ADDRESS_639637]-challenge will be of fered Oral Rehydration 
Solution (ORS) or Gatorade to prevent dehydration, at the same volume as their stool output. 
For documentation purposes of concomitant medications, ORS will  not be considered a 
concomitant medication; however, intravenous (IV) fluids will. 
 
A participant may be administered IV fluids (clinician discreti on) for the following reasons:  
• Participant experiences abrupt onset of diarrhea defined by [CONTACT_497348]/liquid stool of > 300 grams or passage of > 400 grams of loose/liquid stools over 2 
hours. 
• Participant becomes hypovolemic. 
 
 
Protocol v4.2 
16 JAN 2023 30 • It is determined necessary by [CONTACT_497349]/vomiting 
and unable to drink enough to keep up with output, or other rea son. 
 
Hypovolemia is a significant decr ease in blood volume, characte rized by  [CONTACT_5640]:  
• Orthostatic hypotension, confirmed systolic blood pressure (BP)  < 90 mmHg and 
associated symptoms. 
• Significant lightheadedness on standing with a confirmed postur al change in BP or pulse. 
Postural vital signs will be measured laying and 2 minutes afte r standing. A significant 
change will be any of the following: decrease in systolic BP of  > 20 mmHg or diastolic 
BP of > 10 mmHg, or increase in pulse of > 30 beats/min. 
 
Ǥ 
Treatment for severe nausea or vomiting may be needed. Particip ants who experience severe 
nausea or vomiting may be given oral or intravenous (IV) ondans etron (Zofran). 
Ǥ 	
Acetaminophen, ibuprofen, or naprox en may be used to treat feve r or pain. 
Ǥ 
 In addition to above medications other medications may be given  to participants as needed 
for symptom control (e.g., heartburn), or if a medical problem arises (allergic reaction, 
insomnia). The most commonly utilized medication, including the  indication are as follows: 
 
Medication Dosage Indication  
Ondansetron oral dissolving 
tablet 4 mg, 8 mg once, can be repeated 
if not better in 30 minutes Nausea/vomiting  
Ondansetron IV 0.15 mg/kg IV x 1 Vomiting Max 16 mg/dose 
Acetaminophen 500- 1000 mg q 4-6 hours Pain, fever Max 4000 mg/day 
Ibuprofen 400-800 mg q 6-8 hours Pain, fever Max 2400 mg/day 
Naproxen sodium 220-440 mg q 12 hours Pain, fever Max 660 mg/day 
Naproxen 250-500 mg bid Pain, fever Max 1000 mg/day 
Benadryl 25-50 mg oral q 6 hrs prn Itching, insomnia  
Maalox As directed Heartburn, indigestion  
Tums As directed Heartburn, indigestion  
 
͵Ǥ 
Routine discharge is scheduled  for approximately study day 9. T wo consecutive negative stool 
cultures for Shigella  are required before discharge (c an be collected on the same st udy day). If the 
participant has not completed antibiotics, then the remaining d oses of antibiotic will be given to 
the participant for self-adminis tration. Vital signs will be co llected. 
 
 
 
Protocol v4.2 
16 JAN 2023 31 ͶǤ 
Early discharge is permitted in cases where early antibiotic tr eatment has been initiated. The 
participant needs [ADDRESS_639638] taken two doses 
of antibiotic with resolved or resolving clinical symptoms befo re discharge. Remaining doses of 
antibiotic will be given to the participant for self-administra tion. Participants discharged before 
study day 8 will return on day 8 and provide the requisite samp les (stool, blood) as delineated in 
the Schedule of Procedures. 
 
ͷǤ 
Participants will return to clinic 15, 29, 57, and [ADDRESS_639639] 
a 6-month follow-up after the final challenge. Clinic visits du ring follow-up will include vital 
signs assessment, clinical checks, including concomitant medica tions and AEs, and sample 
collection for immunogenicity and exploratory outcome evaluatio ns as per the schedule of events. 
 
͸Ǥ Ȁ
Only concomitant medications approved by [CONTACT_497350]. 
Participants needing to take unapproved or excluded medications  will not be eligible for 
enrollment in this study. Any medication given during the trial  (e.g., acetaminophen or 
antibiotics) will be documented in the participant ’s study chart and on the appropriate page of the 
electronic Case Report Forms (eCRFs). Approved medications that  were being taken prior to, as 
well as during, the course of the trial will also be documented  in this manner. 
XI. STUDY SCHEDULE 
ͳǤ ǡǡ ǣ
Healthy participants will be recruited from the Baltimore, MD-W ashington, DC region and 
surrounding areas (including other states) via IRB-approved adv ertisements, word of mouth, and 
contact[CONTACT_497351]. Contact [CONTACT_497352], electronic methods (including text and email), and mail. Study staff will 
respond to inquiries by [CONTACT_648], text, or email. Study staff will  provide a brief, scripted synopsis 
of the research study that incl udes basic inclusion and exclusi on criteria in compliance with 
the IRB-approved screening protoc ol. Participants who express i nterest in participating in the 
study will be asked to complete a telephone pre-screen to asses s general health status and basic 
eligibility. Potential volunteers determined to be generally he althy and meeting basic 
eligibility requirements will be scheduled for an in-person scr eening. Participants will provide 
written informed consent prior to any study procedures. 
 
ʹǤ 
ʹͲͲǣ
The CIR will use a screening protocol approved by [CONTACT_497343] 
(JHSPH) IRB in recruiting participants for this study. The scre ening protocol is entitled 
“Screening of adult volunteers for eligibility to participate i n clinical studies evaluating 
investigational vaccines, antimicrobial agents, or disease prev ention measures or the pathogenesis 
of infectious agents, ” CIR 200, JHSPH IRB 00010083. Participants will be made aware th at the 
screening process may take several visits to complete.  
 
The following procedures will occur: 
a) Discuss the study screening process and obtain Screening Inform ed Consent from the 
participant. 
b) Ensure that the participant has a clear understanding of the na ture of the screening study by 
[CONTACT_497353] a brief c omprehension examination. Then e nsure the participant 
signed and received a copy of the ICF.  
 
 
Protocol v4.2 
16 JAN 2023 32 c) Elicit a complete medical history, including menstrual and cont raceptive history and/or 
history of surgical sterility for female participants. 
d) Pregnancy prevention counseling for females focusing on the imp ortance of preventing 
pregnancy during study participation, potential risks associate d with pregnancy while 
taking investigational products, and effective contraceptive op tions. 
e) Vital signs will be collected (heart rate, respi[INVESTIGATOR_697], bl ood pressure, and temperature). 
f) Obtain blood for Shigella  titers specific for S. flexneri  2a and S. sonnei.  
 
Additionally, the following activities may occur or be deferred  to a subsequent screening visit: 
a) Administer a complete physical examination. 
b) Provide HIV pre-test counseling, including that the testing is voluntary but necessary for 
study participation, information about HIV testing, transmissio n and prevention, explanation 
of test results, post-test counseling, and result reporting. 
c) Obtain blood for a complete blood count (CBC) with differential , basic metabolic panel, 
ALT, AST, ABO blood typi[INVESTIGATOR_007], HLA-B27 antigen, IgA, Hepatitis B v irus, Hepatitis C virus, 
and HIV testing. Obtain urine sample for toxicology testing, lo oking for the presence of 
amphetamines, barbiturates, opi[INVESTIGATOR_858], phencyclidine, benzodiazep ine, methadone, or cocaine 
metabolites. Screening CBC or chemistries may be repeated if th ere are potentially transient 
abnormalities or if there is concern for an error.  
d) Females will have a serum sample taken for E-HCG testing. 
e) Height and weight measurements. 
 
͵Ǥ Ǧǣ
Approximately 110 healthy, potentially eligible and willing par ticipants will be invited back to 
complete study-specific screening to allow for participants who  do not continue to meet study 
eligibility criteria or wish t o continue in the study. The foll owing procedures will occur during 
this visit: 
 
a) Participants will receive an overview of the study in an indivi dual or group setting and an 
Informed Consent Form (ICF) to read on their own.  
b) Participants will be encouraged to ask questions, and then inde pendently complete a quiz to 
evaluate comprehension of study procedures, requirements, and r isks. They must 
independently take and pass with ൒70% understanding. The participant will be able to retake 
the test once if they do not pass the first time. Study staff w ill meet individually with the 
participant to review the completed comprehension assessment. I ncorrect answers will be 
reviewed with the participant.  
c) Both the participant and staff member obtaining consent will si gn, date, and time the ICF 
and a signed copy of the consent will be given to the participa nt.  
d) Participants will read and agree to comply with the Inpatient U nit Guidelines, Alternate 
Agreement, and Handwashing Best Practice. 
e) Volunteers will be asked to complete and sign a HIPAA medical r ecord release form. 
f) Female volunteers will receive pregnancy prevention counseling.  
g) All participants will receive HIV pre-test counseling as descri bed above, if not completed 
prior.  
h) Inclusion and exclusion criteria will be assessed. 
i) Demographics, medical history, including gender, date of birth,  race, height, weight, and any 
allergies will be collected and/or reviewed. 
j) Vital signs will be collected (heart rate, blood pressure, temp erature). 
k) Research samples will be collected as per schedule of events, i f not already completed.  
l) Complete physical exam will be done.  
m) Functional bowel survey will be completed. 
 
 
Protocol v4.2 
16 JAN 2023 33 n)  All volunteers will be tested for COVID-[ADDRESS_639640] 1-5 days prio r to admission. Any 
volunteer who tests positive for COVID-19 will not be eligible for admission. 
o) As part of the pre-inpatient period, eligible subjects may be a sked to perform a 5-minute 
baseline psychomotor vigilance test (PVT). Additionally, subjec ts will be provided a 
smartphone and actigraphy devices to be worn starting up to [ADDRESS_639641]-discharge follow-up visit (study day 15 ± 2 days). 
 
Attempts will be made to inform participants of their screening  laboratory results either in person 
or over the telephone. Participants with clinically significant  abnormalities (as determined by [CONTACT_1600] [INVESTIGATOR_1461]) may be asked to have additional blood drawn. If  the result(s) is confirmed, 
participants may be referred to their primary care physician. A  copy of the laboratory results may 
be provided to the participant at his/her request.  
 
ͶǤ 
Participants will be considered enrolled in the study upon rece ipt of the Investigational Product. 
 
ͷǤ 
Ǥ ǦʹǦͳǡȋͺͻ ʹȌ
Up to [ADDRESS_639642] provided informed consent and meet  all eligibility criteria will 
be invited and 32 participants wi ll be admitted to the inpatien t unit (each admission). This is 
to allow for some dropout of the volunteers due to ineligibilit y or reversal of consent. Up to 
30 participants each admission will be enrolled into the study and receive challenge as per 
Table 1 . Volunteers who are admitted but not enrolled or do not receiv e challenge at that 
admission will be discharged and will not be followed. 
 On arrival to the unit, the following will be performed: 
x Volunteer will be tested for COVID-19; volunteer must have a ne gative test on admission 
to be admitted to the inpatient unit. 
x Volunteer will be admitted to the unit. Personal items will be reviewed. Unallowed items 
will be stored until discharge.  
x Orientation to the unit. 
x Vital signs (blood pressure, temperature, and heart rate) at le ast twice. 
x Complete physical examination. 
x Assessment for eligibility (inclusion and exclusion criteria). 
x Concomitant medications will be reviewed. 
x Serum pregnancy testing for females; if results are not availab le prior to challenge, urine 
pregnancy testing will be performed on Day 1. 
x Blood will be collected for research, including immunological a ssays and serology.  
x Blood will be collected for baseline assessments: CBC with diff , BMP, ALT and AST. 
x Stool for qualitative and quantitative culture, and immunology (as per schedule of events 
and SSP). In the event a participant is unable to produce a sto ol on Day -2 or -1, at 
admission, stool may be collected any time on the day of admiss ion or on Day 1, until 4 
hours after challenge. Participant's inability to produce a sto ol on Day -2 or -1/Day 1 will 
not be exclusionary for challenge. 
x Salivary IgA (as per schedule of events and SSP). 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP). 
x Pregnancy risk assessment and prevention counseling. 
 
 
 
Protocol v4.2 
16 JAN 2023 34 Ǥ ͳǡȋͻͲʹȌ
x On the day of challenge, participants will receive a light brea kfast and then initiate at 
least a 90-minute fast. 
x Vital signs (BP, heart rate, and temperature) will be collected  4 times: prior to challenge, 
at least [ADDRESS_639643] challenge, and two additional times. 
x A focused physical exam (symptom focused) and evaluation to ass ure that there are no 
changes from admission and ensure the volunteer remains eligibl e for challenge. Solicited 
and unsolicited AEs will be assessed. 
x The alternates or a volunteer who does not continue to meet eli gibility criteria will be 
discharged without challenge. Participants who never received a  challenge dose will not 
be followed. Participants who previously received challenge wil l complete a Day 90 and 
Day 180 follow-up visit (as described in Section ix below). 
 
Ǥ 
x Approximately 1 minute prior to challenge (and within 2 minutes ), participants will drink 
120 mL of bicarbonate buffer (buffer formulation: 13.35 grams o f sodium bicarbonate in 
1000 mL of sterile water for irrigation). 
x For challenge, participants will drink a solution of virulent Shigella  bacteria (as per Table 
1 and described in Section XII, 5), approximately 1500 cfu suspended in 30 mL of 
bicarbonate buffer (for 2457T strain) or saline (for 53G strain ). 
x Participants will be observed for at least [ADDRESS_639644] challenge. 
x Following receipt of the Shigella  challenge inoculum, all stools will be collected for 
weighing, grading and assessment for blood.  
x If a participant develops grade 3 – 5 stools on Day 1, a sample of all grade 3 – 5 stools 
produced that day will be collected for possible culture. Up to  3 stools prior to the start of 
antibiotics should be sent for culture. 
 
Ǥ ͳȂͺǡȋͻͲǦͻ͹ʹȌ
x Vital signs (BP, heart rate, and temperature) at least 3 times a day; once in the morning, 
afternoon, and evening (approximately 6 hours apart). 
x Participants will have a focused PE daily, with the assessment of any new or changes in 
solicited and unsolicited AEs. 
x All medications will be provided by [CONTACT_497354]. 
x All stools will be weighed, graded and assessed for blood. 
x A minimum of one stool sample (no more than 3) will be collecte d daily for culture. If a 
volunteer is unable to provide a stool sample, rectal swabs wil l be obtained (as per SSP). 
x Stool will be processed as per SSP daily while inpatient. (If t he participant does not 
produce a stool or enough stool on any day to obtain all sample s, this will not be 
considered a protocol deviation.)  
x Blood and stool for immunological assessments will be collected  as per the Schedule of 
Procedures.  
x Saliva IgA collection (as per schedule of events and SSP). 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP). 
x Antibiotics will be started on Study Day 6 ([ADDRESS_639645] challen ge) unless early treatment 
criteria are met. 
x Volunteers who have Grade 3 or greater adverse events may get s afety labs (chemistries, 
CBC, liver functions tests) if a c linician feels that they are indicated.  
 
 
Protocol v4.[ADDRESS_639646] will be 
transferred to a higher level of care. 
 
v. ͻǡȋͻͺʹȌ  
Volunteers will be eligible for discharge when symptoms are res olved or are resolving, and 
they have had at least two consecutive stool cultures negative for the challenge strains (can be 
collected on the same study day) and have received at least [ADDRESS_639647]: 
x Focused PE prior to discharge 
x Review of solicited and unsolicited AEs 
x Receive morning dose of antibiotics (if course is not complete)  
x Receive their additional doses of antibiotics to take after dis charge 
x At least one set of vital signs prior to discharge 
 
Volunteers who do not meet criteria for discharge will remain o n the unit and continue: 
x Daily focused PE 
x Vital signs three times a day 
x Receive antibiotics (if not complete) 
x Review of solicited and unsolicited AEs  
x All stools will be weighed, graded and assessed for blood. 
x Up to 3 stool samples and/or rectal swabs will be collected for  culture  
 
Ǥ ͳͷ	Ǧ ȋΪȀǦʹȌȋͳͲͶ ʹȌ
x Interim medical history will be obtained 
x AEs and SAEs will be recorded, including assessment of relatedn ess to challenge or 
antibiotics and severity grade 
x Concomitant medications will be recorded 
x Vital signs (BP, HR, and temperature) 
x Focused PE if participant has any complaints/AEs 
x Blood for safety (CBC w/different ial and basic metabolic panel,  ALT/AST) 
x Blood and stool per Schedule of Procedures 
x Saliva IgA collection 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP) 
 
Ǥ ʹͻ	 ǦȋΪȀǦͶȌȋͳͳͺ ʹȌ
x Interim medical history will be obtained 
x AEs and SAEs will be recorded, including assessment of relatedn ess to challenge or 
antibiotics and severity grade 
x Concomitant medications will be recorded 
x Vital signs (BP, HR, and temperature) 
x Focused PE if participant has any complaints/AEs 
x Pregnancy test (blood or urine; females only, to ensure that th ere was not an early 
pregnancy during the challenge period)  
x Blood and stool per Schedule of Procedures 
x Salivary IgA 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP) 
 
Ǥ ͷ͹	 ǦȋΪȀǦͶȌȋͳͶ͸ ʹȌ
x Participants will be questioned about their health status 
 
 
Protocol v4.[ADDRESS_639648] (AESIs) and SAEs will be ass essed 
x Vital signs (BP, HR, and temperature) 
x Focused PE if participant has any AESIs and SAEs 
x Blood and stool per Schedule of Procedures 
x Salivary IgA 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP) 
 
Ǥ ͻͲȋǦ͹ȀΪʹͺȌ  
ǣȋͳͺͲʹȌ
Participants who receive a second challenge will have their day  90 and day 180 after the 
second challenge. Unless the second challenge is >[ADDRESS_639649] challenge and are not selected  for the second challenge will 
complete a Day 90 outpa tient visit . This visit will include:  
 
x Interim medical history 
x AESIs and SAEs will be assessed 
x Vital signs (BP, HR, and temperature) 
x Focused PE if participant has any AESIs and SAEs 
x Blood for assays as per Schedule of Procedures 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP) 
 
Ǥ Ǧ
The volunteers in groups 1A or 2A will be assessed as to willin gness and eligibility to 
participate in a second challenge (based on criteria Section IX, 4). Up to [ADDRESS_639650] challenge will be readmitted to the inpatien t unit for second challenge, with 
the goal of challenging 20 (1 alternate will be admitted in cas e of loss of eligibility by a 
volunteer). If more than [ADDRESS_639651] s. Due to isolation unit 
constraints there need to be an even number of males and female s to fill the 6 same-gender 
shared rooms.  Additionally, up to 11 naïve volunteers will be admitted to the inpatient unit to 
receive challenge with the goal of challenging 10 participants . 
 
x Participants will be questioned about their health status. 
x AEs and concomitant medications will be assessed. 
x Volunteers will be admitted to the unit. Items from home will b e reviewed and items not 
allowed on the unit will be stored in the locked storage area f or participant safety. 
x Orientation to the unit. 
x Vital signs (blood pressure, temperature, and heart rate) at le ast two times (at least 6 
hours apart). 
x Complete physical examination upon admission. 
x Assessed for eligibility (inclus ion and exclusion criteria). 
x Serum pregnancy testing for females; if results are not availab le prior to challenge, urine 
pregnancy testing will be performed on Day 1. 
x Blood will be collected for immunological assays and serology a s per the Schedule of 
Procedures. 
x Blood will be collected for baseline assessments: CBC with diff , BMP, ALT and AST. 
x Stool for assays as per schedule of events and SSP. In the even t a participant is unable to 
produce a stool on Day -2 or -1, at admission, stool may be col lected at any time on the 
 
 
Protocol v4.2 
16 JAN 2023 37 day of admission or on Day 1, until 4 hours after challenge. Pa rticipants ’ inability to 
produce a stool on Day -2 or -1/Day 1 will not be exclusionary for challenge. 
x Salivary IgA (as per schedule of events and SSP). 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP). 
x Pregnancy risk assessment and prevention counseling. 
 Prior to challenge, any alternate  participants will be discharg ed from the unit prior to 
challenge. Those who had been previously challenged will receiv e follow-up as described 
below. The naïve alternates not previously challenged will not be followed-up after 
discharge. Participants who are readmitted and receive the seco nd challenge will repeat the 
challenge schedule as described above in Section XI, 5. 
 
Ǥ ͳͺͲȀʹ͹Ͳ	Ǧ
All participants who receive at least one dose of challenge wil l complete a Day 180/[ADDRESS_639652] challenge dose and 
will include: 
 
x Functional bowel survey (e.g., Rome IV survey) 
x Participants will be questioned about their health status 
x AESIs and SAEs will be assessed 
x Focused PE if participant has any AESIs and SAEs 
x Blood for assays as per Schedule of Procedures 
x Nasal swab for respi[INVESTIGATOR_497301] (as per schedule of eve nts and SSP) 
 
͸Ǥ 
Routine antibiotic treatment will be given to all participants at about [ADDRESS_639653]-challenge. All 
participants will be treated with trimethoprim 160 mg / sulfame thoxazole 800 mg orally twice 
daily for five days, or ciprofl oxacin (500 mg orally twice dail y for three days), or, alternatively, 
ampi[INVESTIGATOR_10312] (500 mg) orally four times daily for three days.  
 Early antibiotic treatment after challenge may commence when any of the following criteria are 
identified and a study physician considers it to be warranted: 
x When volunteer meets the primary endpoint (clinical definition of shigellosis) 
x Confirmed oral temperature ≥ 39°C (after volunteer has not had anything to drink for about 
20 minutes) 
x Any other reason warranting early treatment in the physician’s opi[INVESTIGATOR_497302], because of illness, a participant is unable to take oral an tibiotics, intravenous antibiotics may 
be given at an appropriate dose based on weight and clinical st atus. 
 
Once the volunteer has met the criteria for discharge, s/he wil l be released with the remaining 
antibiotic treatment to be taken at home. Volunteers taking any  other non-antibiotic medication 
on a chronic basis may continue with that medication unless dir ected otherwise by [CONTACT_3786]. These medications  must be recorded on the appropr iate eCRF. 
 
͹Ǥ 
Participants have the right to withdraw from the study at any t ime and for any reason withdrawal 
does not affect the responsibility of the investigator to treat  the participant for study-related 
conditions. The investigator also has the right to withdraw the  participants in the event of 
intercurrent illness, AEs, or for  administrative/social reasons . 
 
 
 
Protocol v4.[ADDRESS_639654] the scientific va lidity of the study; therefore, 
unnecessary withdrawal should be avoided. Should withdrawals oc cur, efforts will be made to 
ensure participant safety and continued monitoring as thoroughl y as possible. In case of 
participant withdrawal, for whatever reason, every attempt to c omplete a final trial evaluation 
must be made stating the reasons. Withdrawals due to non-attend ance must be followed-up by [CONTACT_497355] n-attendance. 
 
Participants withdrawing from the study after receiving the Shigella  challenge will receive 
antibiotics for outpatient trea tment and will be educated on th e importance of complying with 
treatment and good handwashing.  Attempts will be made to follo w the participant for clearance 
of the challenge organism thr ough collection of stool samples a nd for safety through study day 
29. 
 
ͺǤ 
Blood, stool, saliva and nasal swabs will be collected by [CONTACT_497356]. They will be labelled with the part icipant study numbers, processed 
and stored as per SSP on the inpatient unit or the clinic, and then packed and sent to either the 
CIR laboratory, WRAIR, Antigen Discovery Inc (ADi), IAVI or the  University of Utah as per the 
SSPs and agreed upon shipment schedule. Research microbiology, including the preparation of 
the live inoculum and the culturing of stool specimens, will be  carried out in the laboratory of the 
CIR in the JHSPH.  Immunologic and other research assays (as pe r study schedule) will be 
carried out at the Bacterial Dise ases Branch at WRAIR, the JHSP H CIR Enterics lab, Antigen 
Discovery, Inc (ADi) and the University of Utah.   
 
Samples will be collected based on the Schedule of Procedures. Samples will be stored and 
distributed to various laboratories in compliance with DOT/IATA  standards, guidance from the 
JHU Biosafety Review, and based on the SSP. Samples collected u nder this protocol will be used 
to conduct safety, microbiologic, and immunogenicity evaluation s and other research labs (e.g., 
transcriptomics). Study-related samples will be collected and l abeled according to the relevant 
SSP. 
 
The following sections provide a  listing of procedures and test s to be performed in this protocol at 
designated time points. The maximum volume of blood to be drawn  will not exceed 550 mL over 
any 8-week period, which healthy adults should regenerate withi n this period and which should 
not compromise the health of trial participants. 
 
Clinical Laboratory Tests: 
Standard clinical laboratory tests to determine eligibility of participants and for safety monitoring 
will be carried out at Johns Hopkins Hospi[INVESTIGATOR_307], Johns Hopkins Ba yview Medical Center, or Quest 
Diagnostics in Baltimore City, MD:  
 
a) CBC with cell differential and platelets 
b) Basic metabolic panel  
c) Serum E-HCG 
d) ALT/AST 
e) HLA-B27 antigen testing 
f) IgA testing 
g) HIV assay (4rd generation) 
h) HBsAg ELISA 
i) HCV (3rd generation ELISA with immunoblot confirmation) 
j) Urine for drug toxicology screening 
k) ABO typi[INVESTIGATOR_497303] v4.[ADDRESS_639655] for screening: 
S. flexneri 2a and S. sonnei 53G anti-LPS serum titer  
 
Urine E-HCG and fecal occult blood tests will be performed by [CONTACT_497357] a CLIA waiver. 
 
ͻǤ ǣ
All microbiology of stool for Shigella , both quantitative and qualitative cultures, as well as 
possibly PCR, will be done at the JHSPH research lab. 
 
ͳͲǤ ǣ
Blood, stool, saliva, and nasal swabs will be collected for res earch labs to be completed as per 
SSP at either the SPH research lab or at the Department of Diar rheal Research Laboratory at 
WRAIR, ADi, IAVI/Scripps and the University of Utah and may inc lude, but is not limited to: 
 
1. Blood for Anti-LPS serum IgG and IgA 
2. Blood for serum IgG and IgA against Shigella  antigens 
3. Blood for total IgA and possibly IgG 
4. Blood for alpha-4 beta-7 positive and negative cells and antibo dy from lymphocyte 
supernatant (ALS), memory B-cell assays 
5. Stool for IgA against LPS and potentially Ipa proteins 
6. Stool for inflammatory markers and transcriptomics/proteomics 
7. Stool for microbiome 
8. Stool for qPCR 
9. Serology including bactericidal antibodies 
10. Blood for transcriptomics and proteomics (systems biology) 
11. Blood for antigen arrays (to be sent to ADi) 
12. Blood for identification of potential broadly protective antibo dies (IAVI/Scripps) 
13. Saliva for salivary IgA against LPS and potentially Ipa protein s (to be processed in the 
laboratory of Chris Heaney, JHSPH) 
14. Nasal swab for respi[INVESTIGATOR_497304] (to be sent to th e University of Utah) 
 
ͳͳǤ 
Any unused blood, stool, saliva, or nasal swab specimens will b e stored once the study is 
complete. Samples and data collected under this protocol may be  used only for research purposes. 
No genetic testing will be performed on participant samples. Th ese samples will not be sold or 
used to make commercial products.  
Access to research samples will be limited using locked freezer s. Samples and data will be stored 
using codes assigned by [CONTACT_165106](s).  Data will be kept on password-
protected computers. Only investigators or their designee(s) wi ll have access to the samples and 
data. 
 
Any other research or experimental treatments will be conducted  under other protocols for which 
separate IRB review and approval will be obtained. 
 
During the study, samples may be sent to various research labor atories as per SSP. At the 
completion of the protocol (termination), samples that remain a t JHSPH and data may be 
transferred to a repository (J ohns Hopkins Bloomberg School of Public Health [JHSPH] IRB 
protocol R22.05.04.29.A2). Samples remaining at the Department of Defense will be maintained 
as per their SOP. 
 
 
 
Protocol v4.2 
16 JAN 2023 40 In the future, other investigators (both at the Johns Hopkins U niversity (JHU), the DOD and 
outside) may wish to study these sa mples and/or data. In that c ase, IRB approval will be sought 
prior to any sample sharing. Similarly, IRB approval will be ob tained prior to sharing any clinical 
information, with or without patient identifiers that may be li nked to samples being shared. The 
research use of stored, unlinked, or unidentified samples (for example, as a standard for 
immunological analyses) may be exempt from the need for prospec tive IRB review and approval. 
Exemption requests will be submitted in writing to the JHU IRB office and to the PATH 
Research Determination Committee, as applicable, which are auth orized to determine whether a 
research activity is exempt. 
 
Any loss or unintentional destruction of samples, or data (for example, due to freezer 
malfunction, or missing case report forms [CRFs]) that compromi ses the scientific integrity of the 
study or poses a potential breach of confidentiality for the pa rticipant will be reported to the IRB. 
 
Samples will be stored only with  the participant’s permission, which is a requirement for 
participation in the study. The participant may withdraw permis sion for future use of specimens 
at any time. If a participant withdraws his or her permission f or future use of specimens, those 
specimens will be destroyed. In this case, the PI [INVESTIGATOR_469715] t he destruction of all known 
remaining samples and will report this to both the participant and IRB. This decision may not 
affect the participant’s participation in fu ture protocols. 
 
XII. STUDY INTERVENTION/INVESTIGATIONAL PRODUCT 
ͳǤ ShigellaȀ
 
 S. flexneri ʹʹͶͷ͹
The 2457T S. flexneri  2a strain is one of the strains that will be utilized in this study as a 
challenge. It is a well-characterized Shigella  strain manufactured under current Good 
Manufacturing Practice conditions at the WRAIR Pi[INVESTIGATOR_497305] (PBF) in Silver 
Spring, Maryland.  
S. flexneri  2a strain 2457T was originally isolated from a patient with di arrhea in Tokyo in the fall 
of 1954 [17]. The organism was transferred to the WRAIR where i t was used to produce a 
Production Cell Bank of strain 2457T under current Good Manufac turing Practices (cGMP) at 
WRAIR PBF. Validation and characterization of the 2457T MCB (lo t 0589, BPR-321-00) is 
described in the BB-MF 3408 – Type II Master File – Shigella  Species for Vaccine and Challenge 
(Live, Oral) (Serial No. 11 and Serial No. 14) held by [CONTACT_497358]. The 2457T strain has since been used in several studies a t the CIR [19], most recently in 
2015 when 59 volunteers were challenged [26].  The Shigella flexneri  2a 2457T strain is 
susceptible to ciprofloxacin, trimethoprim-sulfamethoxazole and  ampi[INVESTIGATOR_10312]. 
 
Strain dose-finding studies have been completed for the 2457T S. flexneri  2a, and it will be given 
as approximately 1,[ADDRESS_639656] in this study. 
 
 
S. sonneiͷ͵
  
The 53G strain of S. sonnei  was isolated in August 1954 in Tokyo, Japan, from a 5-yr-old m ale 
with diarrhea lasting for 2 days. The strain was described by D upont et al in 1989 [21], 
confirming and establishing the  low-dose virulence of 53G in hu mans. A master cell bank (MCB) 
(Lot 0593) was manufactured by [CONTACT_497359]. The lyophilized 5 3G strain (Lot 1794) of S. 
sonnei  was manufactured under current good manufacturing practices (c GMP) conditions at the 
WRAIR PBF. 
 
 
Protocol v4.[ADDRESS_639657] igators at the Cincinnati 
Children’s Medical Center . In that study, various doses of lyophilized bacteria were giv en to a 
total of 56 adult volunteers. A dose of approximately 1500 cfu resulted in 70% of the volunteers 
having diarrhea [32]. Based on those data, participants will be  given approximately [ADDRESS_639658] in this study. S. sonnei  is sensitive to ciprofloxacin, 
trimethoprim-sulfamethoxazole, and ampi[INVESTIGATOR_10312].  
 
The disease manifestation of infection with orally administered  wild-type S. flexneri 2a strain and 
S. sonnei  53G strain will be evaluated.  
 
ʹǤ 
The challenge strains are stored as 1.0 ml aliquots ( S. flexneri  2457T) with 1.8 x 108 cfu/mL or 
2.0 mL aliquots of S. sonnei  53G with 2 x109 cfu/mL. The tubes are in cryostorage tubes held at -
80qC +/- 10qC under controlled conditions at the WRAIR PBF. Labels of the s trains are in 
Figures 2 and 3 below. 
 
Figure 2: Production Cell Bank for 2457T S. flexneri  2a 
Production Cell Bank for 2457T S. flexneri  2a 
BPR No.: BPR-322-01 
Lot No. : __ 1617___________ 
Contents: 1.0 ml  
Cautions: For Manufacturing Use Only; Viable 
organism  
Date of Mfg:  27 Jan 10 
Manufactured By: [CONTACT_454683], Silver Spring, MD [ZIP_CODE] 
  
 
Figure 3: Shigella sonnei strain 53G 
Shigella sonnei strain 53G 
BPR No.: BPR-1094-00 
Lot No. : ___ 1794__________ 
Contents: 2.0 ml 
Cautions: New Drug – Limited by [CONTACT_4496] (or United 
States) law to investigational use  
Date of Mfg:  25 Feb 13 
Manufactured By: [CONTACT_454683], Silver Spring, MD [ZIP_CODE] 
 
͵Ǥ ǡ
 
 S. flexneri ʹʹͶͷ͹
The Shigella  flexneri 2a 2457T challenge vials are stored at -80°C ± 10°C for short-term  storage 
and in liquid nitrogen for long-term storage. The challenge str ain will be transferred on dry ice from 
the WRAIR PBF to the CIR Enterics Research Laboratory at JHSPH,  utilizing a temperature 
monitoring device, logged in and stored at -80°C ± 10°C in a lo cked and temperature-monitored 
freezer.  Any use of these vials will be done under the supervi sion of the CIR Enterics Research 
Laboratory, JHSPH and tracked in an accountability log.  Any vi als remaining at the end of the 
study will be disposed of (via autoclaving) or returned to WRAI R for use in non-clinical research 
studies at the direction of study Sponsor and after all IP moni toring is completed. 
 
 
 
Protocol v4.2 
16 JAN 2023 42 Colony forming units (cfu) are not routinely monitored during f rozen storage because the master 
cell bank is subcultured twice during inoculum preparation, and  the total number of surviving 
organisms in the original frozen ampule is not critical. Noneth eless, strain stability is confirmed 
by [CONTACT_497360] (TSB)-containing Congo red d ye since virulent Shigella  bind 
this dye and grow as red colonies. In addition, the identity of  isolated colonies used as a source of 
the inoculum for volunteers is confirmed as S. flexneri  2a by [CONTACT_497361] 2 
antiserum. 
 
 S. sonnei ͷ͵

The S. sonnei  53G vials are stored at -80°C (±10°C) freezer at the WRAIR PBF . Prior to 
administration, the requisite number of vials will be transferr ed to the research lab at the CIR 
Enterics Research Laboratory at JHSPH, logged in and stored at -80°C ± 10°C in a locked and 
temperature-monitored freezer. Any use of these vials will be d one under the supervision of the 
CIR Enterics Research Laboratory, JHSPH and tracked in an accou ntability log. Any vials 
remaining at the end of the study will be disposed of (via auto claving) or returned to WRAIR for 
use in non-clinical research studies at the direction of study Sponsor and after all IP monitoring is 
completed.  
ͶǤ 
The details of challenge strain preparation will be in the SSP.   The challenge strains will be 
prepared by [CONTACT_497362].  
 S. flexneri ʹʹͶͷ͹
For the 2457T S. flexneri  2a strain, fresh, plate grown organisms will be used for chall enge 
inocula. Approximately 48 hours before challenge, a vial of the  cGMP Master Cell Bank will be 
thawed. The GMP cell bank is plated onto 5 plates containing tr ypticase soy agar (TSA), to which 
Congo red (CR) dye (0.01%) has been added.  The plates are stre aked for isolation to yield well-
separated colonies and then incubated at 37°C r 1o C for 22 ± 2 hours. After incubation, six 
small, smooth, CR-positive coloni es are tested for agglutinatio n with commercial S. flexneri  Type 
2 antiserum (Denka Seiken Ltd., Japan). If these colonies give strong and rapid agglutination 
reactions, 10 well-isolated CR-positive colonies are pi[INVESTIGATOR_497306] a bacterial 
suspension in 3 mL of phosphate buffered saline (PBS).  This su spension is used to inoculate 
multiple TSA plates to yield confluent growth (~6 plates for 30  volunteers, plus 2-3 extra plates 
as back-up in case of individual plate contamination).  After g rowth for 22 hours at 37°C r 1o C, 
the TSA plates are visually screened for purity, growth is re-c hecked for agglutination in 
antiserum and cells are harves ted in sterile PBS (pH 7.4). For this step, [ADDRESS_639659] ate is collected with a sterile 
pi[INVESTIGATOR_8459], pooled and diluted in PB S to the target dose (1.5x103 CFU/ml) based on target OD [ADDRESS_639660] udy volunteers within 4 hours of 
preparation. 
 
 S. sonnei ͷ͵

The day of challenge, vials will be removed from the freezer an d placed on ice to thaw for 30 
minutes. Then 2 mL of cold (2- 8 ˚C) sterile water for injection (SWI) are added to each vial.  To 
ensure complete rehydration of the challenge strain along with homogeneous mixing of the vial’s 
contents, the vials remain on ice for another 15 minutes with i ntermittent swirling of the 
suspension. Vials will then be combined and diluted in cold, 0. 9% USP sterile saline to arrive at 
the desired concentration. The diluted challenge material is ke pt on ice until administration. 
During reconstitution, an aliquot is removed for testing by [CONTACT_497363]. The CFU total  in the challenge inoculum that are 
 
 
Protocol v4.2 
16 JAN 2023 43 Form I is calculated according to study specific procedures and  the reconstitution time is 
documented.  
 
ͷǤ 
Participants will be challenged with approximately 1.5x103 cfu of S. flexneri  2a strain 2457T or 
1.5x103 cfu of S. sonnei strain  53G. 
 Participants will fast for 90 minutes prior to ingesting the ch allenge inoculum. A sodium 
bicarbonate (USP-grade) solution of 2 g/150 ml water will be pr epared. Each participant will 
drink 120 ml of this buffer one minute prior to ingesting the c hallenge inoculum, to neutralize 
gastric acidity. The bicarbonate buffer is prepared from USP-gr ade sodium bicarbonate by 
[CONTACT_116125] 13.35 grams of sodium bicarbonate in 1000 mL of ster ile water for irrigation.  Within 
2 minutes, participants will drin k the challenge inoculum (1.5 x 10
3 cfu) dissolved in either the 
remaining 30 mL of buffer (for the S. flexneri  2457T strain) or saline (for the S. sonnei 53G 
strain). 
 
Participants will fast for an additional [ADDRESS_639661] the whole dose, this will be documented; however, the pa rticipant will not be rechallenged 
or replaced. After at least [ADDRESS_639662] vital signs taken and will be free to 
move about the unit. 
 
͸Ǥ 
The investigator must ensure that the investigational product i s stored as specified in the protocol 
and in a secured area, with access limited to authorized study personnel. The investigator must 
maintain accurate records of the receipt of all investigational  product, including date received, 
amount received and disposition. A record will be maintained th at includes the dispensation date, 
amount of investigational product dispensed, initials and ident ification number. 
 
Any use of the challenge vials will be done under the supervisi on and direct oversight of the 
Research Pharmacy and JHU Laboratory. The laboratory staff or R esearch Pharmacist will 
maintain a strain accountability log which tracks the status of  all vials received. Any vials 
remaining at the end of the study will be returned to WRAIR or destroyed by [CONTACT_497364]. If destroyed, the investigator, 
in accordance with S ponsor’s  specifications, will document the destruction of any investiga tional 
product. 
XIII.  ASSESSMENT OF SAFETY   
Safety monitoring will be conducted throughout the study; there fore, safety concerns will be 
identified by [CONTACT_218909], clinic s taff, clinical monitor, research monitor, 
and the Sponsor.  
 Study Safety Management: The research monitor and PI [INVESTIGATOR_497307]. A d ata 
safety monitoring board (DSMB) is not required for this study. 
 
Research Monitor: A qualified physician with previous experience in vaccine biolo gy and infectious 
diseases will be appointed as Re search Monitor. Contact [CONTACT_179714], references and responsibilities 
of the Research Monitor will be included in the Safety Manageme nt Plan (SMP). Briefly, the 
Research Monitor will review any SAEs that occurred during the trial and any additional safety data 
 
 
Protocol v4.[ADDRESS_639663] the following responsibilities: 
x Evaluate ongoing safety data and make recommendations in order to ensure participants ’ safety as 
required 
x Be available for consultation by [CONTACT_497337] m through the period of the clinical 
study in which there is an interaction with human participants 
x Be available to review all SAEs and other unanticipated problem s involving risk to participants  
x Provide clinical advice, in accordance with the study protocol,  on the clinical management of 
participants. This advice may include, but is not limited to: 
o Decisions on participants who have “borderline” eligibility for enrollment  
o Confirmation and discussion of treatment decisions for difficul t clinical situations 
 
Protocol Safety Review Team (PSRT): The Protocol Safety Review Team (PSRT) will consist of 
the PATH Medical Officer, the PI [INVESTIGATOR_497308] w ill be responsible for conducting 
periodic reviews of accumulating safety data and of trial condu ct throughout the trial.  Details on the 
responsibilities and processes of the PSRT, including periodici ty of meetings and content of reports, 
will be provided in the Safety Management Plan. In addition to safety review, the PSRT may elect to 
discuss trial conduct issues that impact study integrity and/or  participant safety. These may include, 
but are not limited to, data qual ity, critical monitoring findi ngs, and issues with research specimens. 
 
All clinical decisions must be documented, including date, time , and signature. All decisions must be 
communicated to the study PI [INVESTIGATOR_497309], whi ch must be stored with participant 
source documents.  
All safety reports (i.e., SAEs, deviations, unanticipated probl ems involving risk and participant 
deaths) will be submitted to the JHSPH IRB and NMRC IRB per rep orting requirements of each 
regulatory body. 
 
ͳǤ Ǧ
Vital signs (temperature, blood pressure, and heart rate) will be obtained throughout the inpatient 
period and at study visits after discharge as per the study sch edule (see Table 2  for applicable AE 
coding). 
 
Table 2: Reference Ranges and Adverse Event Coding for Vital Si gns Parameters 
Vital Signs  Mild  
 (Grade 1)  Moderate  
 (Grade 2)  Severe  
 (Grade 3)  Potentially Life  
Threatening (Grade 4)  
Heart rate  
 Tachycardia  101–115 116-130  >130  ER visit or hospi[INVESTIGATOR_497310] 50-54a 45–49 <45 ER visit or hospi[INVESTIGATOR_497311] (°C)  
 (°F)  38.0–38.4 
100.4 –101.1 38.5–38.9 
101.2 –102.0 >39.0 
>102.0  
Life threatening hyperthermia 
Blood Pressure 
 Hypertension  
 (systolic, mm Hg) 141–150 151 - 155 >155 ER visit/hospi[INVESTIGATOR_497312]  
(diastolic, mm Hg) 91–95 96 – 100 >100 ER visit/hospi[INVESTIGATOR_497313] v4.2 
16 JAN 2023 45 Vital Signs  Mild  
 (Grade 1)  Moderate  
 (Grade 2)  Severe  
 (Grade 3)  Potentially Life  
Threatening (Grade 4)  
Hypotension  
(systolic, mm 
Hg)b 85–89 80 – 84 <80 ER visit/hospi[INVESTIGATOR_497314] 1 bradycardia will not be considered an abnormality for t his study unless judged to be clinically significant by [CONTACT_978] [INVESTIGATOR_497315]. 
 bIf a participant has a baseline systolic BP in the 90’s then a decrease in BP < 10 without associated clinical symptoms will not be 
considered an abnormality for this study unless judged to be cl inically significant by [CONTACT_978]. 
Based on the FDA Guidance for Industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in Prevent ative 
Vaccine Clinical Trials https://www.fda.gov/regulatory-informat ion/search-fda-guidance-documents/toxicity-grading-scale-health y-
adult-and-adolescent-volunteers-enrolled-preventive-vaccine-cli nical 
 
ʹǤ 
A complete physical exam will be conducted during the screening  visit and on Day -2 or -1 as 
part of the screening process. PE to include HEENT (head, ears,  eyes, nose, throat), skin, 
respi[INVESTIGATOR_696], cardiovascular, abdomen/GI, neurological, and musc uloskeletal. Focused physical 
exams (symptom focused), will be conducted prior to receipt of any challenge product, daily 
during participant s’ inpatient stay, and as needed during outpatient visits with sp ecific attention to 
the identification of AEs, AESIs, and SAEs. 
 
͵Ǥ 
Participants will be asked to collect all stools passed on the unit and bring them to the lab for 
assessment and processing. Stools will be weighed and graded ba sed on the following scale [3]: 
x Grade 1, firm formed;  
x Grade 2, soft formed;  
x Grade 3, viscous opaque liquid or semiliquid which assumed the shape of the container;  
x Grade 4, watery opaque liquid;  
x Grade 5, clear watery or mucoid liquid.  
 
Stools defined as grade 3, 4, or 5 are considered to be loose. 
Stools will be observed for presence of gross blood; if a stool  appears grossly bloody, it will be 
tested for blood using a hemoccult card. Stool that is not gros sly bloody will not be tested for 
occult blood. 
 An epi[INVESTIGATOR_497316] [ADDRESS_639664] ’s description . No stools will be weighed during the outpatient period. 
 
ͶǤ 
Venous blood samples will be collected for chemistry, hematolog y, and immunological 
parameters during the screening phase of this study, to provide  a baseline sample, and after 
challenge as per the Schedule of Procedures.  Hematology and ch emistry analyses will be 
performed by a commercial laboratory. Additional specimens may be collected to confirm and 
evaluate any abnormal values and may be obtained as part of the  clinical care of an individual 
participant.  Targeted urine drug screenings are planned for th is study at screening and urine or 
serological screening (including for surreptitious use of antib iotics) may be performed later at the 
discretion of the study clinician. 
 
The clinical toxicity grading scale that will be used as a guid eline is based on the FDA Guidance 
for Industry: Toxicity Grading Scale for Healthy Adult and Adol escent Participants enrolled in 
Preventive Vaccine Clinical Trials and the DAIDS Table for Grad ing the Severity of Adult and 
 
 
Protocol v4.[ADDRESS_639665] will be repeated and 
followed up, if clinically relevant.  Slightly abnormal laborat ory values that remain consistent 
from the time of screening throughout the study will not be rec orded as AEs. 
 
Table 3: Reference Ranges and Adverse Event Coding for Clinical  Hematology Parameters 
Test Normal  Mild 
(Grade 1)  Moderat e 
(Grade 2 ) Severe 
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Hemoglobin (g/dL) 
(for screening purposes only) M: LLN = 11.0 
F: LLN = 10.5      
Hemoglobin, low  M: 10.0 to 10.9 
F:9.5 to 10.4  M: 9.0 to 
<10.0  
F: 8.5 to <9.5 M: 7.0 to <9.0 
F:6.5 to <8.5 M: <7.0 
F: <6.5  
Eosinophils (cells/mm3) 15-500 551-1,500 1,501 -5,000 > 5,000 Hypereosinophi lic 
Leukocytes (white blood cells) 
(cells/mm3) 2,500 to 10,800     
Leukopenia  2,000 to 2,499 1,500 to 1,999 1,000 to 1,499 <1,000  
Leukocytosis  10,801-15,000  15,001- 
20,000 20,001- 
25,000 > 25,000 
Lymphocytes, low (cells/mm3) >650 600 to <650  500 to <600 350 to <500 <350  
Neutrophils, low (cells/mm3) >1,000 800 to <1,000  600to 799 400to 599  <400  
Platelets decreased 
(cells/mm3) ≥125,000  100,000 to 124,999 50,000 to 
<100,000 25,000 to 
<50,000  <25,000  
 
 
Table 4: Reference Ranges and Adverse Event Coding for Blood Ch emistry Parameters 
Test Normal Mild 
(Grade 1) Moderate 
(Grade 2) Severe 
(Grade 3) Potentially Life 
Thre atening 
(Grade 4) 
BUN (elevation) 7-25 26-28 29-31 > 31 Requires dialys is 
Creatinine (elevation)  M: 0.7-1.4 
F: 0.5-1.[ADDRESS_639666] 
 > 1.[ADDRESS_639667] OR 
Increase of > 0.3 mg/dL 
above baseline  > 1.8 to < 3.[ADDRESS_639668] 
OR Increase of 1.5 to < 2.0 x above 
baseline
 ≥ 3.[ADDRESS_639669] OR 
Increase of ≥ 2.0 x 
above baseline  
Glucose, Random (mg/dL)  65 to115     
Hypoglycemia   55 to 64  40 to <55  30 to <40  < 30 
Hyperglycemia   116 to 160  >160 to 250  >250 to 500  > 500  
Potassium (mEq/L; mmol/L ) 3.4 to 5.6     
Hypokalemia   3.0 to < 3.4 2.5 to <3.0  2.0 to <2.5  < 2.0  
Hyperkalemia   >5.6 to <6.0  6.0 to <6.5  6.5 to <7.0  ≥ 7.0  
SGOT/AST (elevation)  M: 10 to 40 
F: 10 to 35 1.25 to <2.[ADDRESS_639670] 2.5 to <5.[ADDRESS_639671]  5.0 to <10.[ADDRESS_639672] ≥ 10.[ADDRESS_639673]  
SGPT/ALT (elevation)  M:9 to 46 
F: 6 to 29 1.25 to <2.[ADDRESS_639674]  2.5 to <5.[ADDRESS_639675]  5.0 to <10.[ADDRESS_639676] ≥ 10.[ADDRESS_639677]  
 
 
Protocol v4.2 
16 JAN 2023 47 Sodium (mEq/L; mmol/L ) 136 to145     
Hyponatremia   130 to <135  125 to <130  121 to <125  ≤ 120  
Hypernatremia   146 to <150  150 to <154  154 to <160 ≥ 160  
 
ͷǤ Ǧ
The following terms, as defined by 21 CFR 312.32, apply to IND safety reporting. 
 

An adverse event is any untoward, undesired, or unplanned event  in the form of signs, 
symptoms, disease, or laboratory or psychological/physiologic o bservations occurring in a 
subject enrolled in the clinical trial. This includes an exacer bation or worsening of pre-
existing conditions or events, intercurrent illnesses, injuries , or vaccine or drug interaction, or 
worsening of abnormal clinical laboratory values.  Anticipated day-to-day fluctuations of pre-
existing conditions that do not represent a clinically signific ant exacerbation need not be 
considered AEs. Discrete epi[INVESTIGATOR_497317] a 
study period will be reported as AEs to assess changes in frequ ency or severity.  Stable, pre-
existing conditions and/or elective procedures are not AEs (inc luding any not recognized or 
not reported prior to study entry) and will be recorded in the Medical History. 
 
AEs will be documented in terms of signs and symptoms observed by [CONTACT_497365] r, with a medical diagnosis 
stated. AEs occurring after informed consent is obtained, but p rior to IP receipt, will be 
documented in the Medical History form within the participant's  eCRF.  
 
 
A “suspected” adverse reaction means any adverse event for whic h there is a reasonable 
possibility that the investigational product caused t he adverse event. For the purpo ses 
of IND safety reporting, “reasonable possibility” means there i s evidence to suggest a 
causal relationship between the investigational product and the  adverse event. 
Suspected adverse reaction implies a lesser degree of certainty about causality than 
adverse reaction, wh ich means any adverse event caused by [CONTACT_497366] t. 
 
ȋ Ȍ
A solicited AE is a predetermine d event, which may reflect safe ty concerns related to the IP.  
This study includes challenge with live Shigella  bacteria, therefore all the symptoms of 
Shigella  illness are expected.  The most common effects of Shigella  infection are listed 
below. These potential Shigella -associated AEs will be solicited daily during the challenge 
phase: 
 
1. Abdominal cramps* 
2. Abdominal pain* 
3. Anorexia (poor appetite) 
4. Arthralgias* 
5. Bloating 
6. Chills 
7. Constipation 
8. Excessive flatulence 
9. Generalized myalgia* 
10. Headache 
 
 
Protocol v4.2 
16 JAN 2023 48 11. Lightheadedness  
12. Malaise* 
13. Nausea* 
14. Tenesmus 
15. Urgency 
 *Constitutional and enteric symp toms that are in the definition  of shigellosis 
 
The following anticipated AEs
 will be documented via clinical assessments during 
the inpatient challenge phase:  
 
1. Diarrhea of any severity (via stool logs) 
2. Dysentery 
3. Hypovolemia 
4. Fever (oral temperature > 100.4° F / 38.0 qC) 
5. Vomiting 
 

An AE of special interest is an AE of scientific and medical concern spe cific to the Sponsor’s 
product or program, for which ongoing monitoring and rapid comm unication by [CONTACT_497367]. Such an event m ight warrant further 
investigation in order to characterize and understand it. 
 
AEs that are considered AESI are the following: 
x Development of a new chronic illness 
x Development of Reactive Arthritis 
x Development of Irritable Bowel Syndrome or other continuing gas trointestinal condition 
 

An adverse event or suspected adverse reaction is considered “s erious” if, in the view of 
either the investigator or Sponsor, it results in any of the fo llowing outcomes:  
x Death 
x Life-threatening adverse event 
x Inpatient hospi[INVESTIGATOR_331325] 
x Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
x Congenital anomaly/birth defect (abortion, stillbirth and any m alformation/disease must 
be reported as an SAE). 
 
Although not considered SAEs, cancers will be reported in the s ame way as SAEs.  
 
Pertinent definitions include: 
x Life threatening - An AE is life threatening if the participant  was at risk of death at the 
time of the event; it does not refer to an event that hypotheti cally might have caused 
death if it were more severe. 
x Disabling/incapacitating - An AE is incapacitating or disabling  if it results in a substantial 
disruption of the participants' ability to carry out normal lif e functions. This definition is 
not intended to include experie nces of relatively minor medical  significance such as 
headache, nausea, vomiting, diarrhea injection site reactions a nd minor accidental trauma 
(e.g., sprained ankle). 
 
 
Protocol v4.2 
16 JAN 2023 49 x Hospi[INVESTIGATOR_059]: In general, hospi[INVESTIGATOR_497318] (usually involving at least an overnight stay)  at the hospi[INVESTIGATOR_497319]'s office or 
outpatient setting. Hospi[INVESTIGATOR_497320] a pre-existing 
condition which did not increase in severity or frequency follo wing initiation of the study 
or for routine clinical procedures (including hospi[INVESTIGATOR_059] f or "social" reasons) that are 
not the result of an adverse event need not be considered as AE s and are therefore not 
SAEs.  
x Routine Clinical Procedure: A procedure which takes place durin g the study and does not 
interfere with the test articl e administration or any of the on going protocol specific 
procedures. 
 
Note:  If anything untoward is reported during an elective proc edure, that occurrence must be 
reported as an adverse event, either `serious' or non-serious a ccording to the usual criteria. 
When in doubt as to whether ‘hospi[INVESTIGATOR_059]’ occurred or was n ecessary, the AE will be 
considered serious. Important med ical events that may not resul t in death, be life-threatening, 
or require hospi[INVESTIGATOR_708], base d upon appropriate medical 
judgment, they may jeopardize the  patient or participant and ma y require medical or surgical 
intervention to prevent one of the outcomes listed in this defi nition. Examples of such 
medical events include allergic bronchospasm requiring intensiv e treatment in an emergency 
room or at home, blood dyscrasias or convulsions that do not re sult in inpatient 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
 
͸Ǥ ȋ Ȍ
The investigator or designee must assign a relationship of each  AE to the receipt of the IP. The 
investigator or designee will use clinical judgment in conjunct ion with the assessment of a 
plausible biologic mechanism, a temporal relationship between t he onset of the event in relation 
to receipt of the IP, and identif ication of possible alternate etiologies including underlying 
disease, concurrent illness or concomitant medications. Every e ffort will be made to explain AEs 
and assess causal relationships, if any, to administration of t he challenge, or antibiotic treatment.   
 
AEs occurring after receipt of the challenge (Day 1) will be as sessed as to their relationship with 
the Shigella  challenge strain or the antibiotic, if applicable. The degree of certainty with which an 
AE can be attributed to these prod ucts (or alternative causes, e.g., natural history of the 
underlying diseases, concomitant therapy, etc.) will be determi ned by [CONTACT_497368]: 
 
x Reaction of similar nature having previously been observed with  Shigella  challenge strains or 
antibiotic administration 
x Published literature accounts supporting causality 
x Temporal relationship with administration 
 
The following guidelines should be used by [CONTACT_497369].  Only a physician or nurse practi tioner can make this determination. 
The investigator will assess causality of all AEs. Non-serious and serious adverse events will be 
evaluated as two distinct types of events given their different  medical nature. If an event meets 
the criteria to be determined ‘serious’ it will be examined by [CONTACT_497370] e event.  
 
Other possible contributors include:  
x Underlying disease 
x Other medication 
 
 
Protocol v4.2 
16 JAN 2023 50 x Protocol-required procedure 
x Other cause (specify) 
 Causality of all AEs will be assessed by [CONTACT_497371]: 
In the investigator’s opi[INVESTIGATOR_1649], the likelihood of the relationship of the AE to challenge 
administration is to be recorded as follows: 
x Related: There is a reasonable causal relationship between the challenge strain administered 
and the AE. 
x Not Related: There is no reasonable causal relationship between  the challenge strain 
administered and the AE. 
 
All AEs will be recorded on the appropriate AE form of the part icipant’s eCRF and recorded 
irrespective of severity or whether or not they are considered related to the challenge inoculum. 
AEs will be tabulated separately for pre-and post-challenge dat a.  
 
͹Ǥ ȂȀ
AEs occurring from the time of consenting through [ADDRESS_639678] will be recorded on the appropriate eCRF (AEs reported prior to challenge will be 
reported in the medical history eCRF). All AEs observed by [CONTACT_497372] a direct question will be 
evaluated by a study investigator or designee and recorded in t he participant eCRF. The nature of 
each event, date of onset, outcome, severity and causality will  be established. Details of any 
symptomatic/corrective treatment will be recorded on the source  documents and entered in the 
appropriate page of the eCRF. AEs will be assessed as to their relationship with the challenge 
strain, the antibiotic (if treatment has started) or the protoc ol.  
 During the inpatient phase, both solicited and unsolicited adve rse events will be assessed, 
whereas at outpatient visits only unsolicited AEs will be asses sed. AEs already documented in the 
eCRF, i.e., at a previous assessment, and designated as ‘ongoin g’ will be reviewed at subsequent 
follow-up assessments. If resolved, documentation in the eCRF w ill be completed. Changes in 
AE severity for solicited events during the inpatient period wi ll be documented as a new event. 
Unsolicited AEs during the inpatient period, and any reported A Es with onset during the 
outpatient period, will be recorded as single events with the h ighest severity for the duration of 
the event entered in the eCRF. 
 
Challenge-specific solicited AEs will be assessed during the in patient phase of the study. Adverse 
events which occur after informed consent is obtained, but prio r to challenge, will not be 
documented as AEs but as medical history, irrespective of sever ity. All AEs will be assessed 
through 28 days after each challenge, documented in the source records, and recorded on the 
eCRFs using accepted medical terms and/or the diagnoses that ac curately characterize the event. 
AESIs and SAEs will be assessed through study completion (appro ximately [ADDRESS_639679] 
challenge). Solicited AEs (listed above) will be recorded as in dividual events. Unsolicited AEs 
may be recorded as a diagnosis. When a diagnosis is known, the AE term recorded on the eCRF 
will be the diagnosis rather than a constellation of symptoms. The investigator will assess all AEs 
for causality, severity, and outcome.  When an event has not re solved by [CONTACT_497373], it will be left open/without an end date on the AE eCRF  and will be updated with end date 
or ongoing at the final visit.  
 
ͺǤ 	Ǧ 
Any SAE deemed related to IP that is ongoing at the time of las t study visit will continue to be 
followed until it is resolved, assessed to be resolved with seq uelae, or assessed to be 
 
 
Protocol v4.2 
16 JAN 2023 51 stable/chronic. SAEs deemed not related to IP that are unresolv ed at the time of the last study will 
be classified as ongoing. Investigators are required to follow related SAEs to resolution, even if 
this extends beyond the prescribed reporting period. Resolution  is the return to baseline status or 
stabilization of the condition w ith the probability that it wil l become chronic. The SAE outcomes 
will be reported to the Sponsor. 
 Investigators are not obligated to actively seek SAEs in former  participants; however, if a SAE 
considered to be related to the IP is brought to the attention of the investigator at any time  until 
closure of the study, the event will be reported. 
 
Investigators should follow-up adverse events at least until th e final study visit. This may include 
repeat safety laboratory analysis. Outcome should be assessed a s: 
x Resolved 
x Resolved with sequelae 
x Severity change (the highest severity in a day will be recorded  in the source documents; for 
solicited events during the inpa tient period, if the severity o n day 1 is moderate, then mild 
and then moderate, it will be entered as moderate for day 1 onl y, then if on day 2 the ongoing 
event is mild, the moderate AE will stop and the AE will be ree ntered as mild; unsolicited 
events that occur during both the inpatient and outpatient peri ods will be entered as single 
events to document the entire duration in the eCRFs, with the h ighest severity recorded for 
the event duration) 
x Ongoing  
x Died 
x Lost to follow-up 
 
ͻǤ 
All AEs will be assessed for sev erity by [CONTACT_093]/desig nee. Inherent in this assessment is 
the medical and clinical consideration of all information surro unding the event including any 
medical intervention required. Each event will be assigned one of the following categories: mild, 
moderate, severe, or life-threatening. The criteria below may b e used for any symptom not 
included in the grading scale. Any grade 4 (life-threatening) A E must be reported as an SAE. 
 
For solicited AEs during the in patient period, the eCRF will do cument daily changes for ongoing 
events. For any solicited AEs with onset during the outpatient period, the eCRF will reflect the 
highest severity for the entire duration of the event. Severity  changes will be documented as 
described above. 
 
Mild Grade 1 Does not interfere with routine activities; minimal level 
of discomfort 
Moderate Grade 2 Interferes with routine activities; moderate level of 
discomfort 
Severe Grade 3 Unable to perform routine activities; significant level 
of discomfort 
Potentially life-threatening Grade 4 Hospi[INVESTIGATOR_497321]-threatening event 
 As defined by [CONTACT_5787] (IC H) guideline for Good Clinical 
Practice (GCP), the term “severe” is often used to describe int ensity (severity) of a specific event 
(as in mild, moderate, or severe myocardial infarction); the ev ent itself however, may be of 
relatively minor medical significance (such as severe headache) . This is not the same as 
“serious”, which is based on participant/event outcome or action  criteria usually associated with 
 
 
Protocol v4.2 
16 JAN 2023 52 events that pose a threat to a participant ’s life or functioning. Seriousness (not severity) serves as 
a guide for defining regulatory reporting obligations. 
 
During the challenge phase of the study, Shigella  disease-specific adverse events will be graded 
in accordance with the table below. 
 
Table 5: Challenge Inpatient Phase Shigella  Infection Solicited Adverse Event/Endpoint 
Reactogenicity/Adverse Event Severity Parameter 
Diarrhea based on highest output 
of loose/liquid stools in any 24-hour period. (A diarrhea epi[INVESTIGATOR_497322] a 48 hour 
window with no grade 3
-5 
stools.)  1- Mild t 2 loose / liquid stools weighing t 200g within 48 hrs. 
or 1 stool weighing ≥300g, not meeting the definition for moderate or severe 
2- Moderate 4 to 5 loose/liquid stools within  24 hours or 401 - 800g of 
loose/liquid stool within 24 hours 
3- Severe^ 
 ≥6 loose/liquid stools within 24 hrs. or >800g of 
loose/liquid stool within 24 hours 
4 Potentially life threatening  
Oral temperature* (t) 1- Mild >100.4oF and <101.1oF (38.0-38.4oC) 
2- Moderate >101.2oF and <102.0oF (38.5-38.9oC) 
3- Severe >102.0oF and < 104 oF (39.0 - 40oC) 
4 > 104 oF or 40oC Life threatening hyperthermia 
Vomiting 1- Mild One epi[INVESTIGATOR_5319] a 24-hour period 
2- Moderate Two epi[INVESTIGATOR_42988] a 24-hour period 
3- Severe Three or more epi[INVESTIGATOR_42988] a 24-hour period 
4 Potentially life threatening consequence of emesis 
Other solicited and non-solicited 
adverse events  1- Mild Discomfort noted, but no disruption of normal daily 
activities; slightly bothersom e; relieved with or without 
symptomatic treatment. 
2- Moderate Discomfort sufficient to red uce or affect normal daily 
activity to some degree; bot hersome; interferes with 
activities, only partially r elieved with symptomatic 
treatment. 
3- Severe Discomfort sufficient to red uce or affect normal daily 
activity considerably; prevents  regular activities; not 
relieved with symptomatic treatment. 
4 Potentially life threatening 
*Oral temperature; no recent hot or cold beverages, eating or ph ysical activity. If temperature is ≥ 100.4 °F every attempt sh ould be made to 
repeat the temperature in about 20 minutes after the participan t has rested with no eating or drinking. If the repeat temperat ure is WNL and 
the investigator feels the repeated temperature is a more accur ate reflection of the participant's real temperature a fever wi ll not be entered 
into the eCRF. ^A subset of more severe diarrhea is ≥10 loose (grade 3 -5) stools with in 24h or ≥1000 gr loose (grade 3 -5) stools within 24h. 
 
 
Table 6: Classification of Intensity of Diarrhea during the Out patient Phase 
 
Diarrh ea Mild 
(Grade 1)  Moderate 
(Grade 2)  Severe 
(Grade 3)  Potentially Life 
Threatening (Gra de 4) 
Loose stools are stools to 
be determined to be grade 
3 - 5 by [CONTACT_15328] 3 loose stools in 24 
hours 4-5 loose stools 
in 24 hours 6 or more loose 
stools in 24 
hours  Requires hospi[INVESTIGATOR_059]  
 
ͳͲǤ 
The PI [INVESTIGATOR_497323]. 
 
ͳͳǤ 
To obtain an unbiased determination of the efficacy outcomes, a n independent outcome 
adjudication committee will blindly evaluate challenge outcome data after completion of all 
 
 
Protocol v4.[ADDRESS_639680] a non-voting role in deliberations.  
The committee voting members will review all potential efficacy -related cases and endpoint data. 
Among the committee’s responsibilities, they will review and co nfirm all primary endpoint cases  
and provide guidance regarding secondary and other endpoint cla ssifications to include 
agreement on objective criteria for classification of endpoints . Specific duties and responsibilities 
will be outlined in the manual of procedures (MOP) prior to the  start of the study. 
ͳʹǤ 
SAE reports will be provided to the Sponsor, research monitor, and IRB(s).  The investigator 
must report SAEs within one calendar day of becoming aware of t he event by [CONTACT_756], fax or e-
mail (if appropriate) to the contacts in Table [ADDRESS_639681] artic les, SAE(s), and date of onset. The 
investigator will not wait for additional information to fully document the event before notifying. 
The first notification will be confirmed by [CONTACT_497374], 
research monitor, and IRB. The report is then to be followed by  [CONTACT_63664] a completed SAE 
Report Form as soon as possible but not more than [ADDRESS_639682] also be reported imme diately. SAE Report Forms 
are to be used for documentation of these various aspects regar ding the event. Hospi[INVESTIGATOR_497324]. 
The research monitor is required to review all unanticipated pr oblems involving risk to 
participants or others, SAEs, and provide an unbiased written r eport of the event.  At a minimum, 
the research monitor will comment on the event outcomes, and in  the case of a SAE or death, 
comment on the relationship to participation in the study.  The  research monitor will indicate 
concurrence or nonconcurrence with the details of the report pr ovided by [CONTACT_093].  
Reports for events determined by [CONTACT_497375]. 
Unanticipated problems involving risk to participants or others , SAEs related to participation in 
the study and all participant deaths will be reported by [CONTACT_648],  by [CONTACT_6968], or by [CONTACT_6972]. A 
complete written report will follow the initial notification. 
ͳ͵Ǥ 
All SAEs must be reported prom ptly to the Sponsor as per [ADDRESS_639683]. Further, the inve stigator should comply with relevant 
study site SOPs on reporting SAEs. The minimum information that  the investigator will provide 
to the Sponsor is specified in Table 8 .  
 
 
 
Protocol v4.2 
16 JAN 2023 54 Table 7: Study Contacts for Reporting Serious Adverse Events 
Sponsor 
 PATH 
Patricia Njuguna , MD 
 
ACS Plaza, 4th floor  
Lenana Road  
P. O. Box [ADDRESS_639684] , Suite E1100 
Baltimore, Maryland [ZIP_CODE]  
Phone: 410 -955-3193  Toll-Free: [PHONE_020] 
Fax: 410 -502-0584 
Email: [EMAIL_9498]  
Research Monitor Anna P. Durbin, MD 
Professor, International Health  
Johns Hopkins Bloomberg School of  Public Health 
[ADDRESS_639685], Room 251  
 
 
Table 8: SAE Information to be Reported to the Sponsor 
Notification 
Method Information to be Provided 
Email or 
Telephone (within 72 hours) IND number, Sponsor study number, name [CONTACT_142098], investigator name [CONTACT_3669] 
[CONTACT_497376], onset date, date of IP admi nistration, severity, relations hip, and participant ’s 
current status 
AND  
Email or Fax Cover sheet or letter 
 Serious adverse event report form 
 Concomitant medication case report form or a list of concomitan t medications 
 Medical record progress notes inc luding pertinent laboratory/di agnostic test results 
NOTE: When submitting SAE reports  via email, the subject line o f each email notification will read as 
follows:  
SAFETY REPORT – IND # _____, Study #_____, Participant# _____, Event term: ___ __ 
 
In order to comply with regulations mandating Sponsor notificat ion of specified SAEs to the FDA 
within [ADDRESS_639686] submit additional in formation as soon as it is available. 
The sponsor will report unexpected SAEs associated with the use  of the challenge strain to the 
FDA as specified at 21 CFR 312.32 (c).  
 
Investigators must follow all relevant regulatory requirements as well as specific policy at each 
institution regarding the timely reporting of SAEs to the local  IRB and research monitor.  
Reporting to the Sponsor does not fulfill the investigator’s duty to report all unantici pated 
problems involving risk to human participants or others to the IRB. The PI [INVESTIGATOR_497325]. 
 
ͳͶǤ 
Unanticipated problems involving risk to participants or others , SAEs related to participation in 
the study and all participant deaths should be promptly reporte d by [CONTACT_648], email, or fax to the 
 
 
Protocol v4.[ADDRESS_639687] safety information provid ed by [CONTACT_1034]’s representative 
to the IRB. All SAEs will be reported to the JHSPH IRB accordin g to IRB guidelines. 
JHSPH IRB contact: [CONTACT_7626] [PHONE_10340]; Fax [PHONE_021]; e-mail : [EMAIL_625]. 
Investigators are required to promptly report adverse events th at fit the following criteria using 
the Problem/Event Report Form: 
Event (including adverse event reports, injuries, side effects,  breaches of confidentiality, or other 
problems) that occurs any time  during or after the research stu dy, which in the opi[INVESTIGATOR_53038]: 
1. Involved harm to one or more participants or others, or placed one or more participants or 
others at increased risk of harm; 
2. Is unexpected (an event is “unexpected” when it is not describe d with specificity in the 
protocol and informed consent document; or if described with sp ecificity, it occurs beyond 
the expected frequency and/or severity identified); and 
3. Is related to the research procedures (an event is “related to the research procedures” if in 
the opi[INVESTIGATOR_497326], it was more likely t han not to be caused by [CONTACT_118689].) 
 
ͳͷǤ Ǧ
A serum sample for pregnancy testing (female participants) will  be collected at the screening visit 
and on Day -[ADDRESS_639688] will be collected (female participants) on Day [ADDRESS_639689] report any pregnancy  in study participants to the 
Research Monitor within 14 calendar days of learning of this oc currence. 
Participants who become pregnant after Day 1 through 29 days af ter each challenge dose will be 
followed to term, and the following information will be gathere d for outcome: date of delivery; 
health status of the mother and child, including the child’s gender, height, and weight. 
Complications and/or abnormalities should be reported, includin g any premature terminations. A 
pregnancy is reported as an AE or SAE only when there is suspic ion that the IP may have 
interfered with the effectiveness of contraception or there was  a serious complication in the 
pregnancy, including a spontaneous abortion or an elective term ination for medical rationale. 
Pregnancies that occur after 29 days after each challenge will not be followed. 
ͳ͸Ǥ Ǧ
Any AE-related withdrawal of conse nt during the study must be r eported immediately  (within 
24 hours of identification) by [CONTACT_497377]. 
 
 
Protocol v4.2 
16 JAN 2023 56 ͳ͹Ǥ Ȁ
The knowledge of any pending compliance inspection/visit by [CONTACT_62673], Office for Human 
Research Protections (Department of Health and Human Services),  or other government agency 
concerning clinical investigation or research, the issuance of Inspection Reports, FDA Form 483, 
warning letters, or actions taken by [CONTACT_497378] t he regulations or requirements 
will be reported immediately to IRBs and the Sponsor. 
The investigator will notify the Sponsor within [ADDRESS_639690] t he review of the current study or 
his/her qualification as an investigator in clinical studies co nducted by [CONTACT_1034]. The Sponsor 
will provide any needed assistance in responding to regulatory audits or correspondence. The 
investigator will permit independent auditors (employees of the  Sponsor or an external company 
designated by [CONTACT_1034]) to verify source data validation of the regularly monitored clinical trial. 
The auditors will compare the entries in the eCRFs with the sou rce data and evaluate the study site 
for its adherence to the clinical study protocol and GCP guidel ines and applicable regulatory 
requirements.  
ͳͺǤ 

The lead investigator will be responsible for the preparation o f a detailed annual synopsis of 
clinical activity, including adverse events, for submission to the Sponsor. Each annual report will 
summarize IND activity for 1 year beginning approximately 3 mon ths before the IND FDA 
anniversary date.  
	
A final study report will be prepared in accordance with “Guida nce for Industry: Submission of 
Abbreviated Reports and Synopses in Support of Marketing Applic ations” and ICH E3 Guideline 
“Structure and Content of Clinical Study Reports” and provided to the  Sponsor for review and 
approval. The Sponsor representative will use this report to pr epare the final clinical study report 
for submission to the FDA.  The investigative team will report all AEs to the Sponsor and the 
local IRB in the appropriate sa fety, annual, and/or final repor ts.  
ͳͻǤ 	
The PI, along with the research monitor, may determine if certa in events warrant discontinuation 
of challenge for all participants in a cohort. If any of the fo llowing events occur, administration of 
the challenge will be discontinued for all participants in that  cohort, and the PI [INVESTIGATOR_497327] a thorough review of the events: 
x The occurrence of one or more serious adverse events (SAEs) det ermined to be related to the 
challenge. 
x Systemic allergic reaction, including but not limited to genera lized urticaria, generalized 
petechiae, or erythema multiforme, occurring in two or more par ticipants in a group.  
Bronchospasm or anaphylaxis occurring in any participant.  
 
Based on prior experience with Shigella  challenge studies, it is expected that some participants 
will have severe AEs (such as severe diarrhea). 
 
AEs which will prompt stoppi[INVESTIGATOR_497328]: 
x The investigator deems that stopp ing test article administratio n is in the best interest of the 
participant.  
 
 
Protocol v4.2 
16 JAN 2023 57  
Furth er chal lenge, in a ccordance with the  proto col, m ay be resume d with  the conc urrence of 
the research monitor , Sponsor, and PI. 
 
ʹͲǤ 
The PI, Research Monitor, IRB, Sponsor or FDA may stop or suspe nd the use of either or both 
challenges at any time. Suspension or termination of research m ust be reported to the PATH 
Office of Research Affairs (ORA) within 72 hours. 
XIV. STUDY MONITORING 
ͳǤ 
Monitoring shall be conducted by a designated contract research  organization according to an 
approved monitoring plan that will be finalized prior to the st art of the study. Local monitoring 
will commence at study initiation, during the study, and at clo seout. 
The study monitor shall be available for consultation with the investigator. The study monitor or 
other authorized representatives of the Sponsor may inspect all  documents and records 
maintained by [CONTACT_093], including, but not limited to, medical records (office, clinic or 
hospi[INVESTIGATOR_307]) and pharmacy records for the participant in this stud y. The clinical study site will permit 
access to such records. The investigator will obtain, as part o f informed consent, permission for 
authorized representatives of th e Sponsor, or regulatory author ities, to review, in confidence, any 
records identifying individuals in this clinical study. 
ʹǤ 
Source documents will be maintained in real-time. Data from the  source documents will be 
entered into the database as per the Data Management Plan. Data  entry will commence when the 
last participant is discharged from the inpatient unit. Priorit y data points may be entered for all 
participants first before remaining data. Outpatient visits wil l be completed, and data will be 
entered into the database within about 3 working days. 
 
͵Ǥ ȀȀ
The investigator will maintain complete and accurate documentat ion of the study, including 
records of medical treatments ex ternal to the research received  during the study, records detailing 
the progress of the study for participants, laboratory reports,  source documents, signed informed 
consent forms, investigational product disposition records, cor respondence with the IRB, the 
study monitor and the Sponsor, AE reports, and information rega rding participant discontinuation 
and completion of the study. All required data will be clearly and accurately recorded by 
[CONTACT_497379]. Only designated study site personnel will record or 
change data in an eCRF.  The investigator will be responsible f or procuring data and for quality 
of data recorded in the eCRFs.  Complete source documentation ( the documents in which data 
collected for the clinical trial are first recorded) is kept fo r each participant in his/her individual 
study chart.  All laboratory specimens, reports, study data col lection, and administrative forms 
will be identified by [CONTACT_266343].  eCRFs using 
coded identifiers will be used to record data for participants enrolled in the study.  Forms, lists, 
logbooks, appointment books, and any other listings that link p articipant ID numbers to other 
identifying information will be stored in a separate, locked fi le in an area with limited access. All 
information regarding study participants is kept in password-pr otected computer files or in locked 
file cabinets that can be accessed only by [CONTACT_497380].  Samples are identified by 
[CONTACT_497381].  Chart information and informat ion from study records is not 
released without written permission of the volunteer. 
 
 
Protocol v4.[ADDRESS_639691]-protected and access is a vailable only to authorized r esearch team members.  
Additionally, each authorized research team member is assigned a level of security clearance 
(also password-protected, with mandatory password changes) for the purpose of limiting access 
to certain areas or functions of the database.  Any information  printed from this database is stored 
in locked files until its use is complete and then shredded. 
For this study, an electronic data capture (EDC) database syste m will be used for the collection of 
the study data. The EDC and the eCRFs will be created by [CONTACT_96002] O Emmes with input from the 
site and the Sponsor. The EDC database system will be designed based on the protocol 
requirements, the approved eCRF layouts and specifications, and  in accordance with 21 CFR Part 
11. The eCRF layouts and specifications define and identify the  applicable source data that will 
be collected and captured into the EDC database system. The app licable source data will be 
electronically transcribed by [CONTACT_497382] i n the EDC database system. The 
investigator is ultimately responsible for the accuracy of the data transcribed on the eCRF. Data 
monitoring and management will be performed in the EDC database  system by [CONTACT_497383]. 
A detailed data management plan (DMP) will be developed by t he designated contract 
research organization and approved by [CONTACT_3476], the PI, a nd the Sponsor.   The DMP 
will explain how all AEs will be coded. Additionally, a data di ctionary and metadata rep ort will 
be com pi[INVESTIGATOR_497329] d atabase. 
XV. STATISTICAL CONSIDERATIONS 
ͳǤ 
Safety, efficacy, and clinical outcome data will be entered int o the eCRFs using standard software 
for data management.  Data will be reviewed and errors correcte d with standard strategies for 
range and consistency checks.  AEs for all participants, regard less of the number of challenge 
doses they have received, will be included in the safety analys is.  The null hypothesis for this 
study is that there is no protection provided by [CONTACT_497384].  
Immunology data will be imported after appropriate immunologica l testing has been completed. 
ʹǤ 
Volunteers will be recruited from the community as per Sections  XI and XX. Volunteers will be 
recruited sequentially into each Cohort/Group. Cohort [ADDRESS_639692] followed by S. flexneri 2a challenge; Cohort [ADDRESS_639693] followed by S. sonnei . A 
group is the subset of the cohort that is admitted to the unit at any given time (4 groups, 1A, 1B, 
2A, and 2B). If more than 21 volunteers from 1A or 2A are willi ng to be included in 1B or 2B, 21 
subjects will be randomly selected from the eligible subjects. Due to isolation unit constraints, 
there needs to be an even number of males and females to fill t he 6 same-gender shared rooms. 
 
͵Ǥ 
 
Safety population 
All subjects who have been screened, consented, and proceeded t o receive the challenge strain.  
This population will serve as the primary analysis population f or the safety endpoints. 
 
Per protocol population  
 
 
Protocol v4.[ADDRESS_639694] no major pro tocol violations that are 
determined to potentially interfere with the immunogenicity ass essment.  This population will 
serve as the primary analysis population for the immunogenicity  endpoints.  The population will 
be adapted by [CONTACT_497385]’ data  up to the time of the disqualifying 
protocol deviation. Membership in this study population will be  determined in a blinded fashion. 
 
ͶǤ 
A statistical analysis plan (SAP) for this study is in developm ent and will be finalized prior to 
database lock. Safety and immunogenicity populations will both be comprised of subjects who 
have been screened, consented, and proceeded to receive the cha llenge strain. Missing data are 
expected to be minimal, no imputation will be performed for mis sing values and data will be 
assumed to be missing at random . SAS version 9.4 (Cary, NC) wil l be used to complete study 
analyses. Due to the descriptive nature of this study no adjust ments for multiple testing will be 
performed. 
 

Baseline data such as demographics, medical history, as well as  disposition of the volunteers 
will be summarized in tables or text in the final study report,  as per the details in the SAP.  
 

Each day of the inpatient period, subjects will be monitored fo r loose stools (grade 3-5 based 
on assessment by [CONTACT_497386]’s  diarrhea definition), diarrhea, 
nausea, vomiting, abdominal pain or cramps, fever, headache, my algia, arthralgia, and 
malaise along with the other solicited symptoms listed above.   
Attack rates of shigellosis will be calculated for all study gr oups using the standard definition 
as follows: (# with endpoint / # receiving inoculum) x 100%. Th ese attack rates will be 
estimated along with 95% confidence intervals (both asymptotic estimates and exact) for each 
study group. Attack rates between Shigella  naïve participants and previously challenged 
participants will be compared using a Pearson’s chi -squared or Fisher’s exact test , as 
appropriate. 
 

All AEs will be summarized and compared between groups. Safety data, including 
reactogenicity, AEs, stool information, specified vital signs, abnormal physical exam findings 
and laboratory tests will be listed by [CONTACT_62444]. This info rmation will be summarized in 
data tables as per the SAP. Additionally, tables will be prepar ed to list each commonly 
observed AE, the number of subjects who experienced an event at  least once, and the rate of 
subjects with AEs. All AEs will be divided into defined severit y grades (mild, moderate, 
severe, and life-threatening).  There will be separate summarie s of SAEs, as well as severe 
AEs, AEs of special interest, S[LOCATION_003]Rs, etc. should they occur.  
 
Descriptive statistics (n, mean, standard deviation, median and  ranges for continuous 
variables, percentages for categorical variables) will be compi [INVESTIGATOR_497291]. 
 

Immunological outcomes will be summarized in a tabular format a nd graphed to demonstrate 
kinetics of response. Qualitative (responder rates) and quantit ative assessments (log 
transformed values) will be analyzed. Median increases (fold ri ses) of antibody 
concentrations and seroconversion rates will be calculated alon g with their 95% confidence 
intervals. Geometric mean titers will also be determined and pr esented with their 95% 
 
 
Protocol v4.2 
16 JAN 2023 60 confidence intervals.  For each assay, the fold-increase will b e considered a response, or the 
threshold for responders or non-responders will be pre-determin ed if possible. This will be 
described in greater detail in the SAP. 
 
Comparisons across groups of single immune parameters reported as continuous variables 
(e.g., reciprocal log10 titers) will be made utilizing t-tests and one-way analysis of variance, 
Wilcoxon rank-sum, or Kruskal-W allis H tests, as appropriate. C omparisons of responses 
within groups over time will be made utilizing appropriate pair ed analyses. Immune 
parameters that are nominal i n nature (e.g., responder status) will be compared using chi-
squared or exact tests, as appropriate. Additionally, compariso ns of immune response 
profiles, assessing multiple immune parameters simultaneously, will be explored utilizing 
multivariable regression models, principal component analyses, and/or other multivariable 
methods, as appropriate. 
 
All hypothesis testing will be conducted using a 2-sided alpha =0.05. 
 
Further details of the statistical analysis plan for secondary and tertiary endpoints, if relevant, 
will be included in the SAP.  
 
ͷǤ 
Presuming a shigellosis rate of 70% in naïve participants, a sa mple size of 16 participants will 
yield 95% confidence intervals (asymptotic estimates) of 48-92% , while a sample size of 8 
participants will yield 95% confid ence interval (asymptotic est imates) of 38-100%. 
Presuming an ability to pool naïve participants (if the cohorts  have a comparable attack rate), 
a sample size of 19 participants in the previously S. sonnei 53G  challenged arm and 16 
participants in the S. flexneri 2457T  naïve arm provides a >80% power to detect a shigellosis 
risk difference of 46 % presuming a ≥70% attack rate in Shigella  naïve participants, while a 
sample size of 11 participants in the previously S. flexneri  2457T  challenged arm and 8 
participants in the  S. sonnei 53G naïve arm provides a >80% power to detect a shigellosis risk 
difference of 60% presuming a ≥70% attack rate in Shigella  naïve participants   (based on a 
Pearson ’s chi-squared test for proportional differences and a 2-sided alpha =0.05). A power 
curve, corresponding to a sample size of 19 participants in the  previously S. sonnei 53G 
challenged arm and 16 participants in the S. flexneri 2457T naïve arm and an attack rate of 
70% in Shigella  naïve participants is provided below.  
 
 020406080100
0.1 0.2 0.3 0.4 0.5Power (%)
Attack Rate in Previously Shigella Challenged ParticipantsPower (%) vs. Attack Rate in Previously Shigella
Challenged Participants
 
 
Protocol v4.2 
16 JAN 2023 61  
 
 
XVI. OBLIGATIONS AND ROLES OF THE SPONSOR, INVESTIGATOR, AND 
STUDY PERSONNEL 
This study will be conducted using GCP and in accordance with a ll federal regulations regarding the 
protection of human participants in research including The Nure mberg Code, The Belmont Report, 
US 21 CFR Part 50 – Protection of Human Subjects, 32 CFR 219 (The Common Rule) and  all 
regulations pertinent to the Department of Defense. 
The investigators agree to conduct the research in strict accor dance with this protocol, the ICH 
Guideline for GCP (CPMP/ICH/135/95), as well as in conformity w ith any federal, provincial or local 
regulations regarding the conduct of clinical studies. The Spon sor and investigator must comply with 
all applicable regulations. I n addition, the investigator must follow local and institutional 
requirements including, but not limited to, IP, clinical resear ch, informed consent and IRB 
regulations. The Sponsor will provide notification to the inves tigator of protocol and amendment 
approvals by [CONTACT_497387]. Except whe re the investigator's signature [CONTACT_322580], it is understood that the term "investig ator" as used in this protocol and on 
source documents refers to the investigator or appropriate stud y personnel that the investigator 
designates to perform a certain du ty. The investigator is ultim ately responsible for the conduct of all 
aspects of the study. Sub-investigators or other appropriate st udy personnel are eligible to sign for the 
investigator on designated source documents. 
All amendments to the protocol, consent form and/or any IRB app roved documents, including a 
change of PI, will be submitted to the Sponsor and IRB(s) for r eview and approval prior to 
implementation. 
XVII.  QUALITY CONTROL AND ASSURANCE 
During the study, the investigator will maintain complete and a ccurate documentation of the study, 
including records detailing the progress of the study for each participant, laboratory reports, eCRFs, 
signed informed consent forms for  each study participant, inves tigational product disposition records, 
correspondence with the IRB, the study monitor and the Sponsor,  adverse event reports and 
information regarding participant discontinuation and completio n of the study. All required study data 
will be clearly and accurately recorded by [CONTACT_497388]. Only designated 
study site personnel shall record or change data in an eCRF. Du ring the study, the investigator will be 
responsible for the procuremen t of data and for quality of data  recorded in the eCRFs. The study 
monitor will ensure accuracy of the eCRFs. 
XVIII.  PROTOCOL DEVIATIONS 
Major protocol deviations are a subset of protocol deviations t hat may significantly impact the 
completeness, accuracy, and/or reliability of the study data or  that may significantly affect a subject's 
rights, safety, or well-being.  Non-emergent/minor deviations a re routine departures that typi[INVESTIGATOR_497330] a participant’s failure to comply with the protocol. Ex amples: missing scheduled visits; 
failing to complete required questionnaire.  
Other-than-minimal-risk changes and all unanticipated major pro blems involving human subjects or 
others will be reported promptly to the IRBs, and no such chang es will be made to the research 
without IRB approval unless necess ary to eliminate apparent imm ediate hazards to human subjects. 
 
 
Protocol v4.[ADDRESS_639695]  participant safety will be pro mptly reported to the Research Monitor, 
IRB, and PATH ORA. Other deviations will be reported at the tim e of continuing review. 
XIX. PROTECTION OF HUMAN SUBJECTS 
ͳǤ 
There are limited funds available to the study for care of stud y-related injury. Although the 
investigator and Sponsor will make every effort to cover the co sts of any study-related injury, full 
coverage cannot be guaranteed, and uncovered costs may fall on participants or their insurers. 
Therefore, participants will be informed that there are limited  funds to cover study-related injury 
care costs and that there is the possibility that they may ulti mately be responsible for at least some 
of the cost of care. 
 
The Sponsor will obtain and maintain appropriate and commercial ly reasonable amounts of 
insurance, including commercial  general liability insurance, an d product and completed 
operations liability insurance, including coverage for the clin ical trial. 
 
ʹǤ Ȁ
Risks Associated with Shigella  Infection : Naturally-acquired illness caused by S. sonnei and S. 
flexneri 2a ranges from mild-to-severe watery  diarrhea that may contain muc us or blood. Nausea, 
vomiting, abdominal crampi[INVESTIGATOR_007], headache, abdominal gurgling or g as, anorexia, fever, muscle 
and/or joint aches, and malaise may occur. For most adults, the  illness is not life threatening but 
often leads to mild-to-moderate dehydration and significant inc onvenience associated with loss of 
sleep and activity. Study facilities will have personnel and re sources capable to manage diarrheal 
illness and potential complications. 
Potential risks associated with Shigella  infection/challenge are not limited to the acute effects of 
disease, but might extend to post-infectious conditions, like r eactive arthritis (characterized by 
[CONTACT_497389], urinary, or gastrointestinal 
systems) or irritable bowel syndrome (IBS) (23). In order to li mit the risk of post-infection 
conditions, history of autoimmune disease or inflammatory arthr itis and positive tests for HLA-
B27 (a marker associated with rea ctive arthritis) are checked a t screening as exclusion criteria. In 
addition, a functional bowel disorder survey will be conducted at screening and at Day 180/270. 
Participants with reported prior history of abnormal bowel patt erns who might be at higher risk of 
this post-infectious sequelae will be excluded. 
Risks Associated with Transmission of Challenge : The Shigella strains have the potential for 
risks to both the environment a nd to the research personnel; ho wever, the risk to the environment 
in regard to potential transmission outside of the CIR facility  is low. There is a minimal risk of 
acquiring Shigella  infection associated with participant inoculum administration,  patient care 
activities on the ward, or processing Shigella -infected stool. The risk to the environment will be 
reduced by [CONTACT_497390], ensuring all participants comply with discha rge criteria (two consecutive 
negative stool cultures for Shigella ), emphasizing the importance of handwashing for participants 
and staff, ensuring proper dispo sal/cleaning of linen, and coho rting participants in the CIR while 
shedding Shigella . Participants will be instructed as to the importance of compl eting the 3- or 5-
day course of antibiotics and this instruction will be document ed. 
 
Risks Associated with Antibiotics : Therapeutic antibiotics for use in this study are licensed, 
approved medications that have been used extensively, and shown  to be very safe with only rare 
 
 
Protocol v4.[ADDRESS_639696] commonly reported side effects for cipro floxacin are gastrointestinal 
symptoms (nausea, vomiting, and diarrhea) in as many as [ADDRESS_639697] been observed. Ciprofloxaci n is not recommended for use in 
pregnancy due to concerns of joint damage to the unborn child ( based on studies in young 
animals). Pregnancy is exclusionary for study participation and  is documented through testing 
prior to study interventions and provided discussion on methods  to prevent pregnancy during 
study. Fluoroquinolones, including ciprofloxacin, are associate d with an increased risk of 
tendonitis and tendon rupture in all ages. The risk of developi [INVESTIGATOR_497331]-associated 
tendonitis and tendon rupture is further increased in older pat ients, usually over 60 years of age, 
in patients taking corticosteroi d drugs, and in patients with k idney, heart, or lung transplants, all 
of whom are excluded from this study. Clostridium difficile -associated diarrhea (CDAD/ 
pseudomembranous colitis) has be en reported with use of nearly all antibacterial agents. 
The most common adverse effects of trimethoprim-sulfamethoxazol e are gastrointestinal (nausea, 
vomiting, anorexia), and allergic skin reactions (rash and urti caria). Rare effects can be severe 
allergic reactions, such as Stevens-Johnson syndrome, toxic epi [INVESTIGATOR_194], hepatitis, and 
hematologic abnormalities. 
The most common adverse reactions (>1% ) of ampi[INVESTIGATOR_497332], vomiting , and nausea, 
rash. 
Risks Associated with Saliva Collection : Risks occasionally associated with saliva collection 
include discomfort and (theoretically) choking . 
 
Risks Associated with Nasal Swab:  Risks occasionally associated with nasal swabs may include 
discomfort with procedure, nasal irritation, or bleeding.  
 
Risks Associated with Venipuncture or IVs : Risks occasionally associated with venipuncture 
include pain and bruising at the site of venipuncture, bleeding , infection (occasionally), 
lightheadedness, and syncope (rarely). IVs may also infiltrate and cause swelling and discomfort. 
 Risks Associated with Wearable Data Collection:  Risks may include feeling uncomfortable about 
wearing a wrist device in public. The wrist band may also cause  some minor wrist irritation.  
 
Risks with Isolation : Volunteers may feel bored or anxious about not being able to l eave the unit 
or being separated from family, friends, and community while th ey are on the unit. The unit will 
be staffed 24/7 with medical and security staff. There will be planned activities to participate in or 
not. There are big screen TVs throughout the unit, games, and a  kitchen and dining area. 
 
Risks Associated with Laboratory Results : There may be physical, psychological, and social risks 
if participants test positive for hepatitis B, hepatitis C, and /or HIV. Participants testing positive 
will be counseled and referred for treatment. 
 
Risks Associated with Collection of Stool : There is no risk associated with collecting stool 
samples; however, risks of using rectal swabs could include mil d discomfort, embarrassment, and 
(very rarely) bleed ing or irritation. 
 
Risks Associated with Post-Infectious Irritable Bowel Syndrome (PI-IBS) : Recent studies also 
suggest an increased risk of PI-IBS following bacterial enterit is. PI-IBS, a functional bowel 
disorder characterized by [CONTACT_497391] p ain associated with changes in 
normal bowel patterns, has been described in a recent systemati c review to occur 6-7 times more 
frequently after an acute enteric infection compared to similar  matched controls without such a 
 
 
Protocol v4.2 
16 JAN 2023 64 history [33]. 
 
Risk of Breach of Confidentiality : A breach of confidentiality in which private health informatio n 
is made public is possible.  Medical records associated with th is protocol are subject to provisions 
of the Privacy Act of 1974, 5 U.S.C., Section 552A, and AR 340- 21.  All data and medical 
information obtained about participants will be considered priv ileged and held in confidence.  
Participants will not be identified by [CONTACT_497392]/presentation of the results.  
The Sponsor and the FDA may inspect the records of this researc h as part of their responsibility 
to oversee research and ensure protection of participants.  Stu dy results and data may be 
published in scientific/medical journals; the identity of indiv idual participants will not be 
disclosed. 
Risk of SARS-CoV-2 Exposure a nd Risk Mitigation: SARS-CoV-2, the virus that causes 
COVID-19 infections and disease, is the cause of the current gl obal pandemic that started in 
2020. COVID-19 can cause respi[INVESTIGATOR_497333].  Symptoms include 
fever, increased cough, shortness  of breath, trouble breathing,  fatigue, chills, body aches, 
headache, sore throat, congestion/runny nose, loss of taste or smell, nausea, and diarrhea. The 
virus can lead to more severe illness including pneumonia, resp iratory failure, heart problems, 
liver problems, blood clots, septic shock, and death.  
It is the intent of the Center for Immunization Research to mit igate risk and provide a safe 
environment for participants while they are inpatient on the un it during the study. The CIR will 
educate and encourage all potential study volunteers to be full y vaccinated with one of the 
COVID licensed/EUA vaccines prior to enrolling in this study. V olunteers will not be required to 
be vaccinated against SARS-CoV-[ADDRESS_639698] will also follow ins titutional guidelines and policies. 
Current recommendations include vaccination with one of the lic ensed/EUA vaccines for all 
adults.  
 
Unvaccinated volunteers will be educated on the risks of not be ing vaccinated. They will sign a 
disclaimer regarding vaccination status and possible exposure t o the virus. Unvaccinated 
volunteers will be strongly encouraged to wear a mask and maint ain social distance from others.  
Depending on the level of COVID illness in the community and cu rrent CDC and JHU 
guidelines, volunteers may be asked to obtain a COVID-[ADDRESS_639699] posit ive for SARS-CoV-2 will not be 
eligible for enrollment. 
 
For staff working on the unit, vaccination will be required.  
 As CDC recommendations evolve and change, we will continue to u pdate our plan to incorporate 
updated CDC recommendations. The addition of precautions or red uced precautions may be 
instituted throughout the study, updated recommendations will b e discussed with volunteers and 
posted in the unit. 
 
 
 
Protocol v4.2 
16 JAN 2023 65 ͵Ǥ 
Participants will be questioned and examined daily for evidence  of infection and diarrhea 
complications. Vital signs will be recorded at least three time s per day. Based on prior studies, 
infected participants tend to develop illness with incubation p eriods of approximately 1-[ADDRESS_639700] common complication, 
dehydration, does not occur. The procedures to institute early oral and/or intrav enous rehydration 
therapy are detailed above. In addition to rehydration therapy,  prospectively defined criteria and 
procedures to institute early ant ibiotic therapy are also fully  described above. In order to ensure 
clinical resolution and limit the potential for secondary sprea d upon discharge, predefined 
discharge criteria have been established. Participants will be discharged from the inpatient phase 
of the study when clinical symptoms are resolved or resolving, they have received at least [ADDRESS_639701] two consecutive stool cultures ne gative for Shigella . 
Systemic or severe gastrointes tinal complications rarely occur with Shigella infection. The 
following clinical findings necessitate immediate consideration  and management of complicated 
enteritis: 
x Physical examination compatible with an acute abdomen 
x Severe GI bleeding (any evidence of GI blood loss other than he moccult positivity only, with 
evidence of hemodynamic instability, decrease in hemoglobin, hy povolemia) 
x Sepsis (high fever: temperature >102ºF [39ºC], rigors, hemodyna mic instability) 
 Any of these findings require prompt clinical management and di scussion with the independent 
Research Monitor and the Sponsor Medical Officer. 
 
The Shigella  strain has the potential for risk to both the environment and to the research 
personnel; however, the risk to the environment in regard to po tential transmission outside of the 
CIR facility is low. The risk to the environment will be reduce d by: 
x ensuring that all human waste products from inpatients are disi nfected with bleach prior to 
disposal 
x ensuring all participants compl y with discharge criteria, empha sizing the importance of 
handwashing for participants and staff 
x ensuring proper disposal/cleaning of linen, and cohorting parti cipants in the CIR while 
shedding 
x ensuring participants will not be discharged until they are no longer shedding the challenge 
strain, as per procedures outlined in the protocol 
 
Participants with prior history of abnormal bowel patterns who might be at higher risk of post-
infectious sequelae are excluded. Predefined criteria to assure  early treatment as appropriate also 
may further reduce risk of post-infectious sequelae and is like ly to reduce the risk associated with 
PI-IBS given the positive association between diarrheal illness  duration and PI-IBS risk [34]. 
 
It is important for this study that volunteers return for the s econd challenge if they are invited to 
do so. We will work with each volunteer to stress this importan
ce, make sure that they are 
available for both challenges, and address any questions or con cerns that they have.  It is also 
important for participants to return for the outpatient visits,  and this will be stressed repeatedly 
with volunteers. We also have some flexibility if volunteers ne ed to alter the dates of outpatient 
visits. 
 
 
Protocol v4.2 
16 JAN 2023 66  
ͶǤ 
There is no benefit that can be  guaranteed to participants for participating in this research study. 
However, there is a potential societal benefit in the developme nt of a vaccine to prevent Shigella . 
XX. INFORMED CONSENT 
The informed consent process and document(s) will be reviewed a nd approved by [CONTACT_497393]. The consent document(s) will contain a full explanation of the possible 
risks, advantages, and alternate treatment options, and availab ility of treatment in the case of injury, 
in accordance with 21 CFR 50. Participants will receive an oral  presentation of the study in language 
(i.e., using lay terms as appropriate) they can understand. Que stions on the purpose of the protocol, 
protocol procedures, and risks to  the participants will then be  solicited. Any question that cannot be 
answered will be referred to the  PI. The participant will be al lowed to take the consent document 
home to consider and discuss it with others. The participant sh ould understand that the study products 
are investigational and are not  licensed by [CONTACT_497394]. Informed consent includes the princi ple that it is critical the participant be 
informed about the principal potential risks and benefits. This  information will allow the participant 
to make a personal risk versus benefit decision and understand the following: 
 
x Participation is entirely voluntary. 
x Participants may withdraw from participation at any time. 
x Refusal to participate involves no penalty. 
x The individual is free to ask any questions that will allow him /her to understand the nature of the 
protocol. 
 
Participants will be given the written, IRB-approved informed c onsent, allowed ample time to read 
the consent, allowed to ask questions about the study, have the  questions answered, and given time to 
decide if he/she would like to participate in the study. To doc ument participants ’ understanding of 
informed consent, immediately before the consent is signed, the  person obtaining consent will 
administer a brief comprehension test. A participant must achieve ≥70% correct to be eligible for 
inclusion in the study. Incorrect answers will be discussed wit h participants to reinforce the consent. 
Participants who fail the comprehension test on the first attem pt will be given one additional 
opportunity, either on the same day or another day, to take the  test after reviewing the quiz, and re-
reading the consent. Participant s failing the comprehension tes t on the second attempt are not eligible 
for study enrollment. No coercion or influence is allowed in ob taining participants ’ consent.  
 A written informed consent document, in compliance with [ADDRESS_639702] be retained by [CONTACT_497395]. Participants will receive copi[INVESTIGATOR_497334].  As part of the consent process, participants wi ll also be asked to read and sign a 
Medical Records/Lab Results Release, with an opportunity to ask  questions, if relevant. Participants 
will also be asked to sign a separate information form for HIV- 1 testing. The consent document 
indicates that by [INVESTIGATOR_59844], the participant, or where appropri ate, legal guardian, permits access to 
relevant medical records by [CONTACT_1034]’s representative and by [CONTACT_284384]. 
 The Sponsor’s representative will submit a copy of the initial IRB- and Sponsor’s representative-
approved consent form to the FDA and will maintain copi[INVESTIGATOR_497335]/ethics committee. 
 
 
 
Protocol v4.2 
16 JAN 2023 67 A description of this clinical trial will be available on http: //www.ClinicalTrials.gov, as required by 
[CONTACT_20008]. 
 
All non-exempt research involving human participants shall, at a minimum, meet the requirement of 
32 CFR 219.116(a)(6) in the Code of Federal Regulations. 
 
ͳǤ ǣ
This study will not include individuals less than 18 years of a ge, incarcerated,  or unable to meet 
the requirements to sign the informed consent form. 
ʹǤ 
A multimedia approach to recruitment will be taken, including t he use of social media. 
Additionally, participants in previous studies that have expres sed interest in participating in future 
trials will be contact[CONTACT_497396]. All study-re lated advertisements will be 
reviewed and approved by [CONTACT_497397], NMRC IRB and Human Rese arch Protections Office 
-Office of Research Protection, if applicable. Participants res ponding to the advertisements by a 
phone call to the center will be screened for eligibility based  on a standard screening 
questionnaire administered by [CONTACT_497398]. Some elements of the inclusion/exclusion 
criteria will be discussed with the participant at that time an d a preliminary determination will be 
made regarding the individual’s eligibility for study participa tion. Active duty military members 
will not specifically be recruited for this study. 
XXI. COMPENSATION 
ͳǤ 
Compensation will occur as detailed below. Compensation will be  provided only for completed 
study procedures designated for c ompensatory payment. If a p articipant  is eligible to 
participate in the investigati onal protocol after screening, an d s/he completes all study 
visits, procedures and follows all the rules s/he will receive the following compensation:  
 
For participants  who complete one inpatient phase:  
x $100 total for screening (only if enrolled in the study or pres ents as an alternate) 
x $3,150 for each inpatient period (as long as all study requirem ents are met) 
x $300 for each of the outpatient study visits 
x $200 bonus for those who complete only 1 challenge including ou tpatient visits, and  
x $300 bonus for those who complete 2 challenges including outpat ient visits 
If a participant completes the study according to the protocol and does not stay additional days on 
the inpatient unit, total compensation is $4,950 for participat ion in one challenge, and $9,100 for 
participation in 2 challenges. 
Volunteers that present to the uni t as an alternate but are not  admitted will receive $100 for 
screening (if not already) and $200 for presenting to the unit (a total of $300). Volunteers who are 
admitted to the unit either for the first or second challenge a nd are discharged prior to challenge 
will receive $100 for screening (if not already received) and $ 250 for each full day on the 
inpatient unit.  
If a participant is not eligible for discharge on day 9 because  of illness or not having 2 
consecutive negative stool cultu re results s/he will receive $3 50 per additional inpatient day. 
 
 
Protocol v4.2 
16 JAN 2023 68 Participants will not be paid for missed outpatient visits and may forfeit some or all of their bonus 
as a result of missed/late visits or non-compliance. 
ʹǤ 
There is no financial compensation for investigators in this st udy. All investigators will be 
required to complete a form for the disclosure of significant f inancial interest. 
͵Ǥ 	
Participants will not be discriminated against on the basis of race, sex, or religion. Due to the 
nature of the study, we have excluded individuals under [ADDRESS_639703] excluded individuals who are over the age o f 50 due to the frequency of 
exclusionary medical conditions. Any individual who is unable t o consent due to any reason will 
not be included in this study. 
XXII.  PRIVACY AND CONFIDENTIALITY 
ͳǤ 
All records pertaining to this protocol will be stored in a loc ked filing cabinet at JHU or at an 
offsite, locked storage facilit y per regulations for a minimum of [ADDRESS_639704] igator will obtain permission 
from the Sponsor in writing before destroying any study records  and the Sponsor will notify the 
investigator in writing when records can be destroyed. Relevant  IRBs will be notified in writing 
prior to destruction of any resea rch records.  Specimens will b e stored indefinitely in the JHU or 
the Shigella  laboratory at WRAIR. 
ʹǤ 
Individual participant  medical information obtained as a result of this study is considered 
confidential and disclosure to third parties, other than those cited below, is prohibited. 
Participant confidentiality wil l be further ensured by [CONTACT_22973] g participant identification 
code numbers and participant in itials. Neither the Sponsor, NMR C nor the JHSPH are 
HIPAA-covered entities.  
Confidentiality agreements may be developed with other clinical  trials groups (e.g., at the 
University of Maryland Vaccine Re search Center or Walter Reed C linical Trials Center), and the 
investigative team may check verbally with these sites to see i f participants have participated 
in studies that would preclude their participation in this stud y. No written list will be 
exchanged with these sites.  
XXIII.  PROTOCOL REVIEW PROCESS 
The protocol will undergo scientific review at PATH and NMRC, a nd ethical review at the CIR. In 
addition to these reviews, the J HU Biosafety Committee and Phar macy and Therapeutics Committee 
will review the protocol. The protocol will also require FDA re view as part of the IND application. 
The IND Sponsor will be PATH. Continuing review will be underta ken in accordance with existing 
regulations. 
XXIV.  PUBLICATION POLICY 
Results of this study will be presented and published after rev iew by [CONTACT_46881]-access 
 
 
Protocol v4.[ADDRESS_639705]. 
 
 
Protocol v4.2 
16 JAN 2023 70 XXVI.  REFERENCES 
1. MacLennan, C.A., et al., Consensus Report on Shigella Controlled Human Infection 
Model: Clinical Endpoints.  Clin Infect Dis., 2019. 69(Supplement_8): p. S591-S595. doi: 
10.1093/cid/ciz891. 
2. Kaminski, R.W., et al., Consensus Report on Shigella Controlled Human Infection 
Model: Immunological Assays.  Clin Infect Dis., 2019. 69(Supplement_8): p. S596-S601. 
doi: 10.1093/cid/ciz909. 
3. Talaat, K.R., et al., Consensus Report on Shigella Controlled Human Infection Model: 
Conduct of Studies.  Clin Infect Dis., 2019. 69(Supplement_8): p. S580-S590. doi: 
10.1093/cid/ciz892. 
4. Porter, C.K., et al., Clinical endpoints in the controlled human challenge model for 
Shigella: A call for standardization and the development of a disease severity score.  
PLoS One., 2018. 13(3): p. e0194325. doi: 10.1371/journal.pone.0194325. eCollectio n 
2018. 
5. Hardy, A.V. and J. Watt, Studies of the acute diarrheal diseases; etiology.  Public Health 
Reports, 1945. 60(3): p. 57-84. 
6. Kotloff, K.L., et al., Global burden of Shigella infections: implications for vaccine 
development and implementation of control strategies.  Bull World Health Organ, 1999. 
77(8): p. 651-66. 
7. Kotloff, K.L., et al., Burden and aetiology of diarrhoeal disease in infants and young 
children in developi[INVESTIGATOR_14696] (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.  Lancet, 2013. 382(9888): p. 209-22. 
8. Liu, J., et al., Use of quantitative molecular diagnosti c methods to identify causes of 
diarrhoea in children: a reanalysis of the GEMS case-control study.  Lancet., 2016. 
388([ZIP_CODE]): p. 1291-301. doi: 10.1016/S0140-6736(16)[ZIP_CODE]-X. 
9. Platts-Mills, J.A., et al., Pathogen-specific burdens of comm unity diarrhoea in developi[INVESTIGATOR_18504]: a multisite birth cohort study (MAL-ED).  Lancet Glob Health., 2015. 3(9): p. 
e564-75. doi: 10.1016/S2214-109X( 15)[ZIP_CODE]-5. Epub 2015 Jul 19. 
10. Estimates of global, regional, and national mo rbidity, mortality, and aetiologies of 
diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015.  
Lancet Infect Dis., 2017. 17(9): p. 909-948. doi: 10.1016/S1473-3099(17)[ZIP_CODE]-1. Epub 
2017 Jun 1. 
11. Kotloff, K.L., et al., Shigellosis.  Lancet., 2018. 391([ZIP_CODE]): p. 801-812. doi: 
10.1016/S0140-6736(17)[ZIP_CODE]-8. Epub 2017 Dec 16. 
12. Khalil, I.A., et al., Morbidity and mortality due to shigella and enterotoxigenic 
Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.  Lancet 
Infect Dis, 2018. 18(11): p. 1229-40. 
13. Black, R.E., K.H. Brown, and S. Becker, Effects of diarrhea associated with specific 
enteropathogens on the growth of children in rural Bangladesh.  Pediatrics., 1984. 73(6): 
p. 799-805. 
14. Lee, G., et al., Effects of Shigella-, Campylobacter- and ETEC-associated Diarrhea on 
Childhood Growth.  Pediatr Infect Dis J, 2014. 33(10): p. 1004-1009. 
15. Olson, S., et al., Travelers' diarrhea: update on the incidence, etiology and risk in 
military and similar populations - 1990-2005 versus 2005-2015, does a decade make a 
difference?  Trop Dis Travel Med Vaccines., 2019. 5:1.(doi): p. 10.1186/s40794-018-
0077-1. eCollection 2019. 
 
 
Protocol v4.2 
16 JAN 2023 71 16. Shaughnessy, H.J., R.C. Olsson, and et al., Experimental human bacillary dysentery; 
polyvalent dysentery vaccine in its prevention.  J Am Med Assoc., 1946. 132: p. 362-8. 
17. DuPont, H.L., et al., The response of man to virulent Shigella flexneri 2a.  J Infect Dis., 
1969. 119(3): p. 296-9. 
18. DuPont, H.L., et al., Immunity in shigellosis. II. Protection induced by [CONTACT_497399].  J Infect Dis., 1972. 125(1): p. 12-16. 
19. Porter, C.K., et al., The Shigella human challenge model.  Epi[INVESTIGATOR_19277]., 2013. 
141(2): p. 223-32. doi: 10.1017/S0950268812001677. Epub [ADDRESS_639706] Dis, 1987. 155(6): p. 1260-5. 
21. DuPont, H.L., et al., Inoculum size in shigellosis and impl ications for expected mode of 
transmission.  Journal of Infectious Disease, 1989. 159(6): p. 1126-8. 
22. Coster, T.S., et al., Vaccination against shigellosis with attenuated Shigella flexneri 2a 
strain SC602.  Infect Immun, 1999. 67(7): p. 3437-43. 
23. Kotloff, K.L., et al., Evaluation of the safety, immunogenicity, and efficacy in healthy 
adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine 
strain EcSf2a-2.  Vaccine, 1995. 13(5): p. 495-502. 
24. Levine, M.M., et al., Pathogenesis of Shigella dyse nteriae 1 (Shiga) dysentery.  Journal of 
Infectious Diseases, 1973. 127(3): p. 261-70. 
25. Harro, C., et al. Shigella flexneri 2a Invaplex [ADDRESS_639707] Shigella flexneri 
2a induces protective immune response in a controlled human infection model . in 
Vaccines for Enteric Diseases . 2017. Albufeira, Portugal. 
27. Samandari, T., et al., Production of IFN-gamma and IL-10 to Shigella invasins by 
[CONTACT_497400] a Shiga toxin-deleted Shigella 
dysenteriae type 1 strain.  (0022-1767 (Print)). 
28. Bodhidatta, L., et al., Establishment of a Shigella sonnei human challenge model in 
Thailand.  Vaccine., 2012. 30(49): p. 7040-5. doi: 10.1016/j.vaccine.2012.09.061. Epub 
[ADDRESS_639708] 12. 
29. Pi[INVESTIGATOR_42959], P., et al., Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, 
WRSS1, in Thai Adults.  Clin Vaccine Immunol., 2016. 23(7): p. 564-75. doi: 
10.1128/CVI.[ZIP_CODE]-15. Print 2016 Jul. 
30. Kotloff, K.L., et al., A modified Shigella volunteer challenge model in which the 
inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.  Vaccine, 1995. 13(16): p. 1488-94. 
31. Taylor, D.N., et al., Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after 
experimental challenge.  Clin Infect Dis, 2006. 
42(9): p. 1283-8. 
32. Frenck, R.W., Jr., et al., Establishment of a Controlled Human Infection Model with a 
Lyophilized Strain of Shigella sonnei 53G.  mSphere, 2020. 5(5). 
33. Thabane, M., D.T. Kottachchi, and J.K. Marshall, Systematic review and meta-analysis: 
The incidence and prognosis of post-infectious irritable bowel syndrome.  Aliment 
Pharmacol Ther, 2007. 26(4): p. 535-44. 
34. Spi[INVESTIGATOR_6942], R. and K. Garsed, Postinfectious irritable bowel syndrome.  Gastroenterology, 
2009. 136(6): p. 1979-88. 
 
 
Protocol v4.2 
16 JAN 2023 72 35.  Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. 20 07. Clinical trials of 
Shigella vaccines: two steps forward and one step back on a lon g, hard road. Nat. Rev. 
Microbiol. 5(7):540-554. doi:10.1038/nrmicro1662. 
 
 
Protocol v4.2 
16 JAN 2023 73 Table 9: Schedule of Procedures for Subjects Receiving One Chal lenge 
Study Phase Outpatient Inpatient Outpatient 
Study Day Screening Screening -2 to -1 1 2 3 4 5 6 7 8 9 15 29 57 90 180 
Compliance Range 
(Days) Day -60 to 
Day -2 Day -30 
to Day -2 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 ±28 
Review Inclusion 
/Exclusion Criteria X  X X              
JH 200 screening 
consent X                 
Study 
briefing/Informed Consent (X) X                
Comprehension 
assessment (X) X                
HIV testing 
information sheet (X) X                
Functional Bowel 
Survey  X                X 
Medical History X X                
Physical 
examination/Focused PE (X) X X X X X X X X X X X (X) (X) (X) (X) (X) 
Vital Signs (BP, HR, 
Temp) X X X X X X X X X X X X X X X X  
Screening Titers to S. 
flexneri  and S. sonnei  
IgG levels X3                 
Hematology/CBC 
w/diff  X  X1          X     
Basic Metabolic panel, 
ALT, AST  X  X1          X     
Urine for toxicology 
testing X (X)                
Hepatitis B, C, and 
HIV   X                 
Serum/Urine 
Pregnancy Test (X) X X (X)          X    
IgA  X (X)                
HLA-B27 
antigen/ABO typi[INVESTIGATOR_007] X                 
COVID-19 testing  X2 X               
Concomitant 
Medications X X X X X X X X X X X X X X    
Clinical 
Check/Medical 
Interview X X X X X X X X X X X X X X X X X 
Collection of AEs4   X X X X X X X X X X X X    
 
 
Protocol v4.2 
16 JAN 2023 74 Study Phase Outpatient Inpatient Outpatient 
Study Day Screening Screening -2 to -1 1 2 3 4 5 6 7 8 9 15 29 57 90 180 
Compliance Range (Days) Day -60 to 
Day -2 Day -30 
to Day -2 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 ±28 
Collections of SAEs or AESIs    X X X X X X X X X X X X X X 
Serology including bactericidal antibodies  X  X        X  X X X X X 
Challenge    X              
Stool weighing, grading, assessed for blood 
   X X X X X X X X X      
Stool culture for Shigella    X (X) X X X X X X X X      
Stool for IgA   X (X)   X    X  X X    
Stool for PCR (RNA later)   X (X) X X X X X X X X      
Stool for Microbiome (RNA Later)   X (X) X X X X X X X X X X X   
Stool for Inflammatory Markers   X (X) X X X X X X X X      
Stool for transcriptomics (RNA 
later)   X (X) X X X X X X X X X     
Blood for transcriptom
ics 
(systems biology) (whole blood) (X) X X (X) X     X   X X    
Blood for Antigen 
Arrays (ADI)   X (X) X  X   X X  X X   X 
Antibody lymphocyte supernatant (ALS)  X      X   X X       
Memory B-Cell   X           X X X X 
Serum cytokines   X (X) X  X   X        
Cytokines stool   X X X X X X X X X X X X    
Salivary IgA   X  X  X  X  X  X X X   
Nasal swab for metagenomics   X  X   X   X  X X X X X 
Start antibiotic therapy         X         
Planned discharge            X      
Study completion (1 
challenge only)                 X 
Post-study safety assessment                 X 
Approximate blood volume 
(mL)#  5 119 63  12.5  74  76.5  84  31 54.5 42 42 52 
(X) event may occur on this day in place of another day. 
 
 
Protocol v4.[ADDRESS_639709] (may be done at local test ing site or home) 1 – [ADDRESS_639710].  
3Screening titers may be drawn within 90 days of enrollment.  
4During the inpatient phase, both solicited and unsolicited adve rse events will be assessed, whereas at outpatient visits only unsolicited AEs will be assessed. 
# Blood volumes are approximate and may change somewhat from th ese numbers; the total volume will not exceed 550 mL in any 8-w eek period. 
 
 
 
Table 10: Schedule of Procedures for Subjects Receiving Two Cha llenges 
Study Phase Outpatient Inpatient Outpatient Inpatient Outpatient 
Study Day  Screening Screening -2 or-1 1 2 3 4 5 6 7 8 9 15 29 57 901 -2to 
-1 1 2 3 4 5 6 7 8 9 15 29/ 
118 57/ 
14
6 90/ 
1801 180/
2701 
Compliance 
Range (Days) Day -60 
to Day -2 Day -30 
to Day -2 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 ±28 
Review Inclusion 
/Exclusion Criteria X  X  X             X X              
JH 200 screening 
consent X                               
Study 
briefing/Informed 
Consent (X) X                              
Comprehension 
assessment (X) X                              
HIV testing 
information sheet (X) X                              
Functional Bowel 
Survey  X                              X 
Medical History X X                              
Physical 
examination/Focused PE (X) X X X X X X X X X X X (X) (X) (X) (X) X X X X X X X X X X (X) (X) (X) (X) (X) 
Vital Signs (BP, 
HR, Temp) X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X  
Screening Titers to 
S. flexneri  and S. 
sonnei  IgG levels X6                               
Hematology/CBC 
w/diff  X  X          X    X3          X     
Basic Metabolic 
panel, ALT, AST  X  X          X    X3          X     
Urine for 
toxicology testing X (X)                              
Hepatitis B, C, 
and HIV   X                               
 
 
Protocol v4.2 
16 JAN 2023 76 Study Phase Outpatient Inpatient Outpatient Inpatient Outpatient 
Study Day  Screening Screening -2 or-1 1 2 3 4 5 6 7 8 9 15 29 57 901 -2to 
-1 1 2 3 4 5 6 7 8 9 15 29/ 
118 57/ 
14
6 90/ 
1801 180/
2701 
Compliance 
Range (Days) Day -60 
to Day -2 Day -30 
to Day -2 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 ±28 
Serum/Urine Pregnancy Test (X) X X (X)          X   X (X)          X    
IgA  X (X)                              
HLA-B27 
antigen/ABO 
typi[INVESTIGATOR_007] X                               
COVID-[ADDRESS_639711]  X4 X              X               
Concomitant Medications X X X X X X X X X X X X X X   X X X X X X X X X X X X    
Clinical 
Check/Medical 
Interview X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Collection of AEs2   X X X X X X X X X X X X    X X X X X X X X X X X    
Collections of 
SAEs or AESIs    X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Serology including 
bactericidal 
antibodies  X  X        X  X X X X X        X  X X X X X 
Challenge    X              X              
Stool weighing, 
grading, assessed 
for blood    X X X X X X X X X      X X X X X X X X X      
Stool culture for Shigella    X  (X) X X X X X X X X     X (X) X X X X X X X X      
Stool for IgA   X (X)   X    X  X X   X (X)   X    X  X X    
Stool for PCR (RNA later)   X  (X) X X X X X X X X     X (X) X X X X X X X X      
Stool for 
Microbiome 
(RNA Later)   X  (X) X X X X X X X X X X X  X (X) X X X X X X X X X X X   
Stool for 
Inflammatory 
Markers   X  (X) X X X X X X X X     X (X) X X X X X X X X      
Stool for 
transcriptomics 
(RNA later)   X  (X) X X X X X X X X X    X (X) X X X X X X X X X     
Blood for transcriptom
ics 
(systems biology) 
(whole blood) (X) X X (X) X    X    X X   X (X) X     X   X X    
Blood for Antigen Arrays (ADI)   X  (X) X  X  X  X  X X   X (X) X  X   X X  X X   X 
 
 
Protocol v4.2 
16 JAN 2023 77 Study Phase Outpatient Inpatient Outpatient Inpatient Outpatient 
Study Day  Screening Screening -2 or-1 1 2 3 4 5 6 7 8 9 15 29 57 901 -2to 
-1 1 2 3 4 5 6 7 8 9 15 29/ 
118 57/ 
14
6 90/ 
1801 180/
2701 
Compliance 
Range (Days) Day -60 
to Day -2 Day -30 
to Day -2 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 - - - - - - - - - - ±2 ±4 ±4 -7/ 
+28 ±28 
Antibody lymphocyte supernatant (ALS) 
 X      X  X  X      X5    X   X X       
Memory B-Cell   X           X X X X           X X X X 
Serum cytokines   X (X) X  X  X        X (X) X  X   X        
Cytokines stool   X X X X X X X X X X X X   X X X X X X X X X X X X    
Salivary IgA   X  X  X  X  X  X X X  X  X  X  X  X  X X X   
Nasal swab for 
metagenomics   X   X   X   X  X X X X X  X   X   X  X X X X X 
Start antibiotic therapy         X              X         
Planned discharge            X              X      
Study completion 
(RE-challenge 
only)                               X 
Post-study safety 
assessment                               X 
Approximate Blood 
volumes  (mL)#  [ADDRESS_639712] their d ay 90 and day 180 after the second challenge. If the second cha llenge is >[ADDRESS_639713]  
a day 90 and a day-2 or -1 visit. 
2During the inpatient phase, both solicited and unsolicited adve rse events will be assessed, whereas at outpatient visits only unsolicited AEs will be assessed. 
# Blood volumes are approximate and may change somewhat from th ese numbers; the total volume will not exceed [ADDRESS_639714] (may be done at local test ing site or home) 1 – [ADDRESS_639715] (may be done at local testi ng site or home) 1 – [ADDRESS_639716].  
5Only subjects returning for second challenge will need ALS draw n on day -2 or -1 second admission (naïve subjects will have pr e-study ALS collected during screening). 
6Screening titers may be drawn within 90 days of enrollment.  
(X) Event may occur on this day in place of another day.  
 